NORTHERN TERRITORY OF AUSTRALIA

POISONS AND DANGEROUS DRUGS ACT
No. 4 of 1983
TABLE OF PROVISIONS

Section

PART XIII - OFFENCES, PENALTIES, INVESTIGATIONS, &c.

PART XIV - MISCELLANEOUS

NORTHERN TERRITORY OF AUSTRALIA

No. 4 of 1983

AN ACT

To regulate the sale, supply, storage, possession and use of poisons and dangerous drugs, and for related purposes

[*Assented to 27 April 1983*]

BE it enacted by the Legislative Assembly of the Northern Territory of Australia, with the assent as provided by the *Northern Territory (Self-Government) Act* 1978 of the Commonwealth, as follows:

PART I - PRELIMINARY

1. SHORT TITLE

This Act may be cited as the *Poisons and Dangerous Drugs Act 1983*.

2. COMMENCEMENT

This Act shall come into operation on a date to be fixed by the Administrator by notice in the *Gazette*.

3. REPEAL

The Acts and Ordinances specified in Schedule I are repealed.

4. SAVINGS

(1) Notwithstanding the repeals effected by section 3, the Acts and Ordinances repealed by that section continue to apply to and in relation to an offence committed against an Act or Ordinance so repealed as if this Act had not commenced.

(2) Notwithstanding the repeals effected by section 3, the Methylated Spirits Regulations made under the *Methylated Spirits Act* as in force immediately before the commencement of this Act shall continue to apply to

G. L. DUFFIELD, Government Printer of the Northern Territory

and in relation to methylated spirits manufactured in, or brought or imported into, the Territory as if those Regulations were a notice under section 87 made by the Chief Medical Officer on that commencement, and they may be repealed or amended accordingly.

(3) Where, immediately before the commencement of this Act, there was in force a warrant issued under an Act or Ordinance repealed by section 3, or an application had been made to a Justice for the issue of such a warrant which had not, at that commencement, been fully dealt with -

(a) that warrant shall continue in force according to its tenor, and all actions may be duly taken or continued under or in relation to it, as if it were a warrant issued under this Act; and

(b) the application shall be dealt with, and all actions taken in relation to it shall be as valid and effective, as if it were an application for a similar warrant made under this Act,

as the case may be.

5. CROWN TO BE BOUND

This Act binds the Crown.

6. INTERPRETATION

(1) In this Act, unless the contrary intention appears -

"British Pharmacopoeia" has the same meaning as it has in the *Therapeutic Goods Act* 1966 of the Commonwealth;

"cannabis" means -

(a) a plant or part of a plant of the genus *Cannabis sativa L*;

(b) an extract, resin or tincture of a plant or part of a plant referred to in paragraph (a); or

(c) a preparation or substance containing -

(i) a plant or part of a plant referred to in paragraph (a); or

(ii) an extract, resin or tincture referred to in paragraph (b);

"Chief Medical Officer" means the person appointed as the Chief Medical Officer under section 5 of the *Public Health Act*;

"coca leaf" means the leaf of *Erythroxylum truxillense*, or the leaf of other species of the genus *Erythroxylum* from which cocaine may be extracted either directly or by chemical transformation;

"cocaine" means methyl-benzoyl laevo-ecgonine ($D^{20°}$ = -16°4 in 20% chloroform) with the formula $C_{17}H_{21}NO_4$;

"dentist" means a registered dentist within the meaning of the *Dentists Registration Act*;

"ecgonine" means laevo-ecgonine ([a] $D^{20°}$ = -45°6 in 5% solution of water) with the formula $C_9H_{15}NO_3H_2O$, and all derivatives of laevo-ecgonine which can be used industrially for its recovery;

"hazardous substance" means a substance specified in Schedule 5;

"hospital" means a hospital within the meaning of the *Medical Services Act* or a private hospital or nursing home within the meaning of the *Private Hospitals and Nursing Homes Act*;

"inspector" means an inspector appointed under section 8, and includes the Chief Medical Officer and a member of the Police Force of the rank of Sergeant, Third Class, or above;

"licensed retailer" means a retailer licensed under Part IV to supply poisons;

"methylated spirit" means -

(a) a spirit that has been methylated, within the meaning of the *Spirits Act* 1906 of the Commonwealth, or denatured;

(b) methyl alcohol or wood spirit;

(c) a spirit to which a methylated substance has been added; or

(d) a drinkable liquid with which a methylated spirit is mixed;

"morphine" means the principal alkaloid of opium having the formula $C_{17}H_{19}NO_3$;

"nurse" has the same meaning as in the *Nursing Act*;

"opium" means the plant *Papaver somniferum* L. or a product of the spontaneously coagulated juice obtained from the capsule of that plant, however small is the content of morphine in that product;

"pharmacist" means a registered pharmacist within the meaning of the *Pharmacy Act*;

"pharmacy" means the premises on which a pharmacist principally conducts his business as such;

"poison" means a substance specified in Schedule 1, 2, 3, 4, 6, 7 or 8;

"prohibited drug" means a substance specified in Schedule II;

"Regulations" means the Regulations made under this Act;

"supply" includes sell and exchange;

"therapeutic use" means a use in or in connection with -

(a) the prevention, diagnosing, curing or alleviation of a disease, ailment or defect in, or injury to, a person or an animal;

(b) the influencing or modifying of a physiological process in a person or an animal;

(c) the testing of the susceptibility of a person or an animal to a disease or ailment; or

(d) the testing of a substance for its efficacy on a person or an animal;

"veterinary surgeon" means a registered veterinary surgeon within the meaning of the *Veterinary Surgeons Act*.

(2) Subject to sub-section (3), a reference in this Act to a substance specified in Schedule II or Schedules 1 to 8 (inclusive) includes a reference to the salts, active principals, alkaloids, derivatives and stereoisomers (and the salts of stereoisomers) of that substance, where the existence of such salts, active principals, alkaloids, derivatives and stereoisomers is possible, and all preparations and admixtures containing any proportion of that substance unless specifically exempted or, in the case of a substance specified in a schedule in Part B of the schedules to this Act, where the salt, active principal, alkaloid, derivative or stereoisomer (or salt of the stereoisomer) is included in another such schedule.

(3) A reference in this section to a substance specified in Schedule II does not include a reference to a substance or thing that is also specified in Schedule IV.

(4) Where, in this Act or the Regulations, a reference is made to a poison, substance or thing for which there is a description by that name in the British Pharmacopoeia, the reference is to the poison, substance or thing so described.

7. DELEGATION

(1) The Chief Medical Officer may, by instrument in writing, delegate to a person any of his powers and functions under this Act, other than this power of delegation.

(2) A power or function delegated under this section, when exercised or performed by the delegate, shall, for the purposes of this Act, be deemed to have been exercised or performed by the Chief Medical Officer.

(3) A delegation under this section does not prevent the exercise of a power or the performance of a function by the Chief Medical Officer.

8. INSPECTORS

The Chief Medical Officer may appoint a person to be an inspector for the purposes of this Act.

9. POWERS OF INSPECTORS

An inspector may -

(a) enter, at any reasonable time -

(i) premises registered under this Act;

(ii) the business premises of a person licensed or otherwise authorized under this Act to supply poisons; or

(iii) the premises of a person authorized under this Act to possess and use a Schedule 4, 7 or 8 substance for a purpose, other than therapeutic use on the prescription of a medical practitioner, dentist or veterinary surgeon;

(b) enter, at any time, premises in or on which he believes, on reasonable grounds, a poison or hazardous substance is being produced, prepared, manufactured, used, supplied, administered or kept in contravention of this Act;

(c) inspect stocks of poisons or hazardous substances in or on premises referred to in paragraph (a) or (b);

(d) inspect and take copies of, or extracts from, records required to be kept under this Act;

(e) question the occupier, owner of, or person employed in, premises referred to in paragraph (a), or a person in or on premises referred to in paragraph (b), concerning the receipt into or onto, storage or use in or on or disposal from those premises of poisons or hazardous substances, and related matters;

(f) seize a substance which he believes, on reasonable grounds, to be a poison or hazardous substance, where he has reasonable grounds for believing that the substance has been unlawfully obtained or is being, or is intended to be, used for an unlawful purpose or in contravention of this Act; or

(g) order the withdrawal from supply of a poison or hazardous substance which is not packed or labelled in accordance with the requirements of this Act or the Regulations or the *Containers for Hazardous Substances Act*.

PART II - MANUFACTURE OF POISONS

10. DEFINITION

In this Part, "poison" does not include a preparation made up -

(a) by a medical practitioner, dentist or veterinary surgeon for the treatment of an individual patient or animal;

(b) by a pharmacist on the prescription of a medical practitioner, dentist or veterinary surgeon; or

(c) for subsequent use by the person making up the preparation, provided that the preparation is not supplied to any other person.

11. MANUFACTURER TO BE REGISTERED

Subject to this Act, a person shall not produce or manufacture a poison unless the premises on or in which the poison is produced or manufactured are registered under this Part and the poison is a poison, or a poison of a class of poisons, entered in the register in respect of those premises.

Penalty: $2,000 or imprisonment for 12 months.

12. REGISTRATION OF MANUFACTURER'S PREMISES

(1) The owner or occupier of premises on which poisons are or are intended to be produced or manufactured may apply to the Chief Medical Officer to have those premises registered for the production or manufacture of poisons.

(2) An application under sub-section (1) shall include -

(a) the name, address and occupation of the applicant;

(b) the nature of the operations to be carried out on the premises and the poison or class of poisons to be included in those operations;

(c) the name, address and occupation of the person who is to be responsible for the operations to be carried out on the premises;

(d) details of the proposed arrangements to be made for the security against theft or unlawful removal of poisons manufactured, produced, stored or used on the premises;

(e) a plan of the premises showing the nature of the operations to be carried out in each section of the premises and the nature and location of security devices; and

(f) such other details as the Chief Medical Officer thinks fit,

and shall be accompanied by the prescribed fee.

(3) The Chief Medical Officer may register premises that are the subject of an application under sub-section (1) if he is satisfied that, having regard to the nature of the operations to be carried out and the poisons involved -

(a) the person nominated in the application to be responsible for the operation to be carried out on the premises is a fit and proper person to have control of those operations;

(b) the premises are suitable for the purposes of the production or manufacture of poisons; and

(c) the proposed security arrangements for the premises are adequate to safeguard from theft or unlawful removal poisons produced or manufactured on the premises.

(4) Registration under sub-section (3) shall be effected by the Chief Medical Officer causing to be entered in a register kept for that purpose -

(a) the name, address and occupation of the owner or occupier of the premises;

(b) the address of the premises;

(c) the name, address and occupation of the person referred to in sub-section (3)(a);

(d) the nature of the operations to be carried out on the premises; and

(e) the poison or class of poisons that may be produced, manufactured or used on the premises.

(5) As soon as practicable after the registration of premises under this section, the Chief Medical Officer shall provide the owner or occupier, as the case may be, of the premises with a certificate of registration bearing the details appearing in the register in relation to the premises.

(6) Registration under this Part shall, unless sooner cancelled, remain in force for 12 months and may be renewed for further periods of 12 months -

(a) on application for renewal, in the prescribed form, being made to the Chief Medical Officer by the registered owner or occupier of the premises; and

(b) on the payment of the prescribed fee.

13. TRANSFER OF REGISTRATION

(1) The Chief Medical Officer may, in his discretion, on the application of the registered owner or occupier of premises registered under this Part, transfer the registration of those premises from the name of the person appearing on the register as the owner or occupier to the name of the new owner or occupier of the premises and amend the certificate of registration accordingly.

(2) The Chief Medical Officer may remove the name, address and occupation of a person shown in the register as the person responsible for the operations carried out on premises registered under this Part and may substitute the name, address and occupation of another person -

(a) on application being made in the prescribed form by the registered owner or occupier of the premises; and

(b) if the Chief Medical Officer is satisfied that that other person is a fit and proper person to have control of the operations being or to be carried out on the premises,

and amend the certificate of registration accordingly.

14. DISPLAY OF CERTIFICATE OF REGISTRATION

The owner or occupier of premises registered under this Part shall -

(a) subject to section 12(5) and to paragraph (b), display and keep displayed his certificate of registration in or on the premises while they remain so registered; and

(b) forward his certificate of registration to the Chief Medical Officer when so required by the Chief Medical Officer.

Penalty: $200.

15. CANCELLATION OF REGISTRATION

The Chief Medical Officer may cancel the registration of premises under this Part if -

(a) structural alterations are made to the registered premises; or

(b) there is any change in the operations being carried out on, or in the security arrangements in respect of, the premises,

without his prior written approval.

16. POWERS OF NOMINATED PERSON

A person responsible for the operations being carried out on premises registered under this Part, or a person acting on his behalf, may -

(a) on the premises, be in possession of a poison referred to in the certificate of registration issued under this Part and carry out such operations in relation to it as are specified in that certificate; and

(b) supply a poison to a person who is authorized under this Act to supply or administer that poison to another person.

PART III - CONTROL OF WHOLESALERS

17. WHOLESALER TO BE REGISTERED

(1) A person shall not store a poison for supply by wholesale unless the premises on which the poison is stored are registered under this Part and the poison is a poison, or a poison of a class of poisons, entered in the register in respect of those premises.

Penalty: $2,000 or imprisonment for 12 months.

(2) For the purposes of sub-section (1), premises registered under Part II shall be deemed to be registered under this Part in respect of a poison, or a poison of a class of poisons, in relation to those premises, entered in the register kept under that Part.

18. APPLICATION FOR REGISTRATION

(1) The owner or occupier of premises on which poisons are or are intended to be stored for supply by wholesale may apply to the Chief Medical Officer to have those premises registered for the storage of poisons.

(2) An application under this section shall include -

(a) the name, address and occupation of the applicant;

(b) the poisons to be stored on the premises;

(c) the name, address and occupation of the person who is to be responsible for the storage of poisons on the premises;

(d) details of the proposed arrangements to be made for the security against theft or unlawful removal of poisons stored on the premises;

(e) a plan of the premises showing the nature and location of security devices; and

(f) such other details as the Chief Medical Officer thinks fit,

and shall be accompanied by the prescribed fee.

(3) The Chief Medical Officer may register premises that are the subject of an application under sub-section (1) if he is satisfied that, having regard to the poisons proposed to be stored on the premises -

(a) the person nominated in the application to be responsible for the storage of those poisons is a fit and proper person to be so responsible;

(b) the premises are suitable for the storage of poisons; and

(c) the proposed security arrangements for the premises are adequate to safeguard from theft or unlawful removal poisons stored on the premises.

(4) Registration under sub-section (1) shall be effected by the Chief Medical Officer causing to be entered in a register kept for that purpose -

(a) the name, address and occupation of the owner or occupier of the premises;

(b) the address of the premises;

(c) the name, address and occupation of the person referred to in sub-section (3)(a); and

(d) the poison or class of poisons to be stored on and supplied from the premises.

(5) As soon as practicable after the registration of premises under this section, the Chief Medical Officer shall provide the owner or occupier, as the case may be, of the premises with a certificate of registration bearing the details appearing in the register in relation to the premises.

(6) Registration under this Part shall, unless sooner cancelled, remain in force for 12 months and may be renewed for further periods of 12 months -

(a) on application for renewal, in the prescribed form, being made to the Chief Medical Officer by the registered owner or occupier of the premises; and

(b) on the payment of the prescribed fee.

19. TRANSFER OF REGISTRATION

(1) The Chief Medical Officer may, in his discretion, on the application of the registered owner or occupier of premises registered under this Part and the payment of the prescribed fee, transfer the registration of those premises from the name of the person appearing in the register as the owner or occupier to the name of the new owner or occupier of the premises and amend the certificate of registration accordingly.

(2) The Chief Medical Officer may remove the name, address and occupation of a person shown in the register as the person responsible for the storage of poisons on premises registered under this Part and may substitute the name, address and occupation of another person -

(a) on application being made in the prescribed form by the registered owner or occupier of the premises; and

(b) if the Chief Medical Officer is satisfied that that other person is a fit and proper person to have control of the storage of poisons on the premises,

and amend the certificate of registration accordingly.

20. DISPLAY OF CERTIFICATE

The owner or occupier of premises registered under this Part shall -

(a) subject to section 18(5) and to paragraph (b), display and keep displayed his certificate of registration in or on the premises while they remain so registered; and

(b) forward his certificate of registration to the Chief Medical Officer when so required by the Chief Medical Officer.

21. CANCELLATION OF REGISTRATION

The Chief Medical Officer may cancel the registration of premises under this Part if -

(a) the premises are used for the storage of a poison other than a poison in respect of which the premises were registered; or

(b) there is any change in the security arrangements in respect of the premises,

without his prior written approval.

22. POWERS OF NOMINATED PERSON

A person responsible for the storage of poisons on premises registered under this Part, or a person acting on his behalf, may -

(a) on the premises, be in possession of a poison specified in the certificate of registration issued under this Part in relation to the premises; and

(b) supply a poison specified in the certificate of registration to a person who is authorized under this Act to supply or administer that poison to another person.

PART IV - CONTROL OF RETAILERS

23. RETAILERS TO BE LICENSED

(1) A person shall not supply a poison by retail unless he is licensed under this Part to supply that poison by retail or is employed by a person who is so licensed.

Penalty: $1,000 or imprisonment for 12 months.

(2) For the purposes of sub-section (1), a pharmacist, medical practitioner, dentist or veterinary surgeon shall be deemed to be licensed under this Part in respect of the poisons he is permitted by or under this Act to supply, prescribe or administer.

24. APPLICATION FOR LICENCE

(1) A person may apply to the Chief Medical Officer for a licence to supply a poison by retail.

(2) An application under sub-section (1) shall include -

(a) the name, address and occupation of the applicant;

(b) the nature and location of the premises intended to be used by him for the storage and supply of the poison;

(c) the poison or class of poisons that is intended to be supplied; and

(d) such other details as the Chief Medical Officer thinks fit,

and shall be accompanied by the prescribed fee.

(3) Subject to sub-section (4), the Chief Medical Officer may grant to an applicant a licence to supply by retail a poison if he is satisfied that -

(a) the applicant is a fit and proper person to be granted such a licence; and

(b) the premises proposed to be used for the storage and supply of the poison are adequate for that purpose.

(4) A licence granted under this section does not authorize the person to whom it is granted to supply -

(a) a Schedule 3, 4 or 8 substance; or

(b) a Schedule 2 substance, where the premises in respect of which the licence is granted are located within 40 kilometres, by road, of a pharmacy.

(5) A licence granted under this Part shall specify in the licence document -

(a) the poison or class of poisons that the licensee is authorized to supply; and

(b) the premises that may be used for the storage and supply of that poison or a poison included in that class of poisons.

(6) A licence granted under this Part shall, unless sooner cancelled, remain in force for 12 months and may be renewed for further periods of 12 months -

(a) on application for renewal, in the prescribed form, being made by the licensee during the 28 days immediately preceding the expiration of his licence; and

(b) upon the payment of the prescribed fee.

25. DISPLAY OF LICENCE

A person licensed under this Part shall -

(a) subject to paragraph (b), display and keep displayed his licence document in or on the premises specified in the licence; and

(b) forward his licence document to the Chief Medical Officer when so required by the Chief Medical Officer.

26. TERMS AND CONDITIONS OF LICENCE

(1) A licence granted under this Part may be subject to such terms and conditions as the Chief Medical Officer thinks fit and specifies in the licence document.

(2) The Chief Medical Officer may cancel a licence granted under this Part if -

(a) the licensee is convicted of an offence against this Act;

(b) the licensee does not comply with the conditions specified in the licence document; or

(c) he considers it to be in the public interest so to do.

27. LIMITATION ON RIGHT OF SUPPLY

A person licensed under this Part, or a person employed by him may, on the premises specified in the licence document, be in possession of the poison or a poison of a class of poisons specified in the licence document and supply that poison -

(a) in the case of a Schedule 1 substance - to a person who has attained the age of 18 years who is personally known to him or is known to an adult person, known personally by the licensee or person employed by him, as the case may be, who is accompanying that first-mentioned person;

(b) subject to section 24(4), in the case of a Schedule 2 or 6 substance - to any person; and

(c) in the case of a Schedule 7 substance - to a person to whom, under section 54, he may supply that poison.

PART V - SUPPLY OF POISONS BY PHARMACISTS, MEDICAL PRACTITIONERS, DENTISTS AND VETERINARY SURGEONS

28. SUPPLY BY PHARMACISTS

(1) Subject to this section and section 35, a pharmacist, or a person employed by him, may produce, manufacture or supply -

(a) a Schedule 1 substance -

(i) where the substance is included in a proprietary prescription intended for therapeutic use;

(ii) in accordance with a written prescription of a medical practitioner, dentist or veterinary surgeon; or

(iii) to a person who has attained the age of 18 years who is personally known to him or who is accompanied by an adult person, known personally by the pharmacist or person employed by him, as the case may be, who is accompanying that first-mentioned person;

(b) a Schedule 2, 3 or 6 substance to any person;

(c) a Schedule 4 or 8 substance -

(i) to, or in accordance with a written prescription of, a medical practitioner (including a person who is entitled to practise as a medical practitioner under a law in force in a State or another Territory of the Commonwealth), dentist or veterinary surgeon; or

(ii) to a person authorized in writing by the Chief Medical Officer to possess and use the substance; or

(d) a Schedule 7 substance -

(i) to a person authorized in writing by the Chief Medical Officer to possess and use the substance; or

(ii) to, or in accordance with a written prescription of, a medical practitioner, dentist or veterinary surgeon authorized in writing by the Chief Medical Officer to possess, use or prescribe that substance.

(2) Subject to this Act, a Schedule 3 substance may be supplied only by a pharmacist or a person under the direct supervision of a pharmacist.

(3) A poison supplied in accordance with a written prescription of a medical practitioner, dentist or veterinary surgeon shall be made up for supply by a pharmacist or a person under the direct supervision of a pharmacist.

(4) A pharmacist, or person employed by him, shall not supply a Schedule 4 or 8 substance to, or in accordance with a written prescription of, a person who is not a registered medical practitioner within the meaning of the *Medical Practitioners Registration Act* unless he believes, on reasonable grounds, that the person is, or was at the time of writing the prescription, entitled to practise as a medical practitioner under a law in force in the State or another Territory of the Commonwealth in which the prescription was written.

(5) Nothing in this section entitles a pharmacist, or a person employed by him, to administer a substance referred to in this section except to the extent that a person to whom he supplies it may lawfully administer that substance to himself or to a person in respect of whom it is supplied.

29. SUPPLY OF SUBSTANCES FOR THERAPEUTIC USE

(1) Subject to this section and section 31 and any other law in force in the Territory, a medical practitioner, dentist or veterinary surgeon may supply a Schedule 1, 2, 3, 4, 7 or 8 substance for the therapeutic use of a particular person or animal.

(2) Subject to section 31, a dentist may sell or supply a Schedule 8 substance only for or in relation to the treatment of a dental condition.

(3) Subject to section 31, a medical practitioner may sell or supply a Schedule 8 substance only for or in relation to the treatment of a prescribed medical condition.

(4) Subject to section 31, a medical practitioner or veterinary surgeon may sell or supply a Schedule 7 substance only if he has been authorized in writing by the Chief Medical Officer to possess, sell and supply that substance.

(5) In this section -

"sell" includes issue a prescription for;

"supply" includes administer and having in possession for the purpose of supply or administration.

30. PHARMACIST NOT TO HOLD CERTAIN SUBSTANCES

The Chief Medical Officer may, by notice in writing to a pharmacist, direct the pharmacist not to hold on premises in which he conducts his business a Schedule 8 substance or a Schedule 8 substance specified in the notice except to the extent that is reasonably necessary to enable him to fulfil a prescription after obtaining the substance from a place nominated by the Chief Medical Officer, and the pharmacist shall, accordingly, comply with and not contravene the direction.

Penalty: $2,000 or imprisonment for one year.

31. MEDICAL PRACTITIONER, &c., NOT TO POSSESS, &c., CERTAIN SUBSTANCES

The Chief Medical Officer may, in his discretion, by notice in writing to a medical practitioner, dentist or veterinary surgeon, prohibit the medical practitioner, dentist or veterinary surgeon from having in his possession, supplying, administering or prescribing a Schedule 8 substance and that person, accordingly, shall not have in his possession, supply, administer or prescribe that substance.

PART VI - PRESCRIPTIONS

32. APPLICATION

Unless the contrary intention appears, this Part applies to all prescriptions issued by a medical practitioner, dentist or veterinary surgeon for the supply of a Schedule 1, 4, 7 or 8 substance.

33. CONTENTS OF PRESCRIPTIONS

Every prescription to which this Part applies shall -

(a) include the name, professional qualifications, address and telephone number of the person issuing it;

(b) include the date of its issue;

(c) include the name and address of the person to whom the prescription was issued;

(d) be written in ink and signed by the person who issued it;

(e) include a statement of the quantity of the substance to be supplied and, where the substance is to be supplied on more than one occasion, include a statement of the quantity to be supplied on each other occasion, and the period that is to elapse before resupply;

(f) where it is issued by a dentist - bear on its face the words "FOR DENTAL PURPOSES ONLY";

(g) where it is issued by a veterinary surgeon - bear on its face the words "FOR ANIMAL TREATMENT ONLY"; and

(h) include directions for the taking, application or administration of the substance.

34. PERIOD OF EFFECT OF PRESCRIPTIONS

(1) Subject to this section, a prescription issued in accordance with this Act shall remain in effect only for the period of 6 months from the date of its issue.

(2) A prescription for the supply of a Schedule 8 substance shall remain in effect only for the period of 2 months from the date of its issue.

(3) A person shall not supply to another person a substance that is required under this Act to be supplied only on prescription unless there is a prescription in effect in respect of that supply.

Penalty: $1,000 or imprisonment for 6 months.

35. ENDORSEMENT ON PRESCRIPTIONS

(1) A pharmacist who supplies a substance in accordance with a prescription to which this Part applies shall, subject to sub-section (2), endorse on the face of the prescription -

(a) the date of supply; and

(b) the word "CANCELLED",

(2) Where a prescription is such that it may be used more than once, the pharmacist who supplies a substance in accordance with the prescription shall endorse on the face of the prescription the date of such supply by him of the substance and, where the supply is the last authorized by the prescription, the word "CANCELLED".

36. RECORD OF PRESCRIPTIONS

(1) Subject to this section, a pharmacist shall, as soon as practicable after it is filled, record in a book kept for that purpose, or in some other form approved by the Chief Medical Officer, such details of each prescription filled by him or his employees as the Chief Medical Officer, in writing, directs.

Penalty: $200.

(2) Records kept under this section, and copies of the prescription form endorsed in accordance with section 35 and recorded under sub-section (1), shall be retained by the pharmacist for 2 years after the date of the last entry in the record book or other form.

Penalty: $200.

(3) A pharmacist who supplies a Schedule 8 substance in accordance with a written prescription shall, within 7 days after that supply, forward to the Chief Medical Officer -

(a) the cancelled prescription; or

(b) where that prescription authorizes supply on a later occasion - a copy of the prescription.

Penalty: $200.

37. SUPPLY IN AN EMERGENCY

(1) Subject to this section, a pharmacist may supply a Schedule 1, 4, 7 or 8 substance to a person without a prescription where the pharmacist -

(a) believes on reasonable grounds that the situation requires urgent supply; and

(b) has been requested by telephone by a medical practitioner (including a person who is entitled to practise as a medical practitioner under a law in force in a State or another Territory of the Commonwealth), dentist or veterinary surgeon to supply that substance to that person.

(2) Where a pharmacist supplies a substance in pursuance of sub-section (1), he shall, as soon as practicable after that supply, obtain a prescription from the medical practitioner, dentist or veterinary surgeon who requested him to supply that substance or, if no such prescription is provided to him within a reasonable time but not later than 3 days after the date of the supply, report in writing to the Chief Medical Officer the details of that supply.

38. POSSESSION, &c., OF SCHEDULE 8 SUBSTANCE

A person may have in his possession, attempt to obtain and use in accordance with the conditions for its use subject to which it was prescribed, a Schedule 8 substance prescribed for use by him, or an animal under his control, by a medical practitioner, dentist or veterinary surgeon.

PART VII - HOSPITALS

39. LIABILITY FOR SAFE STORAGE IN HOSPITALS

(1) A pharmacist in charge of a pharmacy at a hospital shall be responsible for the safe storage of all poisons received at the hospital and the supply of those poisons in accordance with this Act.

(2) A pharmacist employed at a hospital shall not supply a poison to a person other than -

(a) a nurse employed at the hospital and in accordance with a written requisition of the nurse in charge of a ward or department of the hospital;

(b) a medical practitioner or dentist employed at the hospital and in accordance with a written requisition of that medical practitioner or dentist; or

(c) subject to this Act, in accordance with a prescription issued in accordance with this Act by a medical practitioner or dentist.

(3) A Schedule 1, 3, 4, 7 or 8 substance supplied to or on the written requisition of a nurse in charge of a ward or department of a hospital shall be held by her for the purpose of administration, and shall not be administered except -

(a) to a person who is a patient in that ward or department; and

(b) on the directions of a medical practitioner.

(4) As soon as practicable after a medical practitioner gives a direction for administering a Schedule 1, 3, 4, 7 or 8 substance to a patient in a ward or department of a hospital, he shall sign an entry in that patient's medical record to the effect that he authorized the administration of that substance and, in the case of a Schedule 8 substance, that entry shall be made and signed before the substance is administered.

Penalty: $200.

40. REGISTER OF SCHEDULE 8 SUBSTANCES IN WARDS

(1) The nurse in charge of a ward or department of a hospital, or of a health centre, shall enter in a register kept for that purpose full details of -

(a) all Schedule 8 substances supplied to or for use in that ward or department or in or by that centre; and

(b) each occasion on which a Schedule 8 substance is administered to a patient in that ward or department or in or of that centre.

Penalty: $200.

(2) Details recorded for the purposes of subsection (1)(b) shall include -

(a) the time and date the substance is administered;

(b) the amount administered;

(c) the name of the patient;

(d) the name of the person authorizing the treatment;

(e) the name and signature of the person administering the substance; and

(f) the name and signature of a person referred to in section 41 who witnessed the administration of the substance.

41. ADMINISTRATION OF SCHEDULE 8 SUBSTANCE TO BE WITNESSED

A Schedule 8 substance shall not be administered to a patient in a ward or department of a hospital, or of a health centre, unless there is present at the time of the administration of the substance a person, other than the patient, who can read English and who witnesses its administration.

PART VIII - MEDICAL KITS

42. AUTHORIZATION OF POISONS IN MEDICAL KITS

The Chief Medical Officer may, in writing, authorize a person to possess a specified quantity of a specified poison where that poison is included in a medical kit and that person may possess that poison accordingly.

43. ADMINISTRATION FROM MEDICAL KITS

(1) A person authorized under section 42 to possess a Schedule 4 or 8 substance shall administer that substance only -

(a) to a person whose medical condition, in the opinion of the person administering it, requires its administration; and

(b) where the advice or personal attendance of a medical practitioner is not reasonably available.

(2) Where a Schedule 4 or 8 substance is administered in circumstances described in sub-section (1), the person administering it shall, as soon as practicable after administering it, report in writing to the Chief Medical Officer the details of its administration, including details of the kind referred to in section 40(2)(a) to (e) inclusive.

Penalty: $200.

PART IX - RECORDS

44. MANUFACTURERS TO KEEP RECORDS

A person responsible under this Act for the operations carried out on premises registered under Part II shall keep a record, in a form approved by the Chief Medical Officer, of -

(a) the date of receipt and the quantity and the name and address of the supplier, of each shipment of a poison received into the premises;

(b) the quantities of poisons manufactured, produced or compounded with other substances on the premises, together with the quantities of preparations containing a poison that are produced on the premises;

(c) the date and quantity of each supply of a poison from the premises, together with the name and address of the person to whom the supply was made; and

(d) such other matters as the Chief Medical Officer requires to be recorded.

Penalty: $200.

45. WHOLESALERS TO KEEP RECORDS

A person responsible for the storage of poisons on premises registered, or deemed to be registered, under Part III shall keep a record, in a form approved by the Chief Medical Officer, of -

(a) the date of receipt and the quantity, and the name and address of the supplier, of each shipment of a poison received into the premises;

(b) the date and quantity of each supply of a poison from the premises, together with the name and address of the person to whom the supply was made; and

(c) such other matters as the Chief Medical Officer requires to be recorded.

Penalty: $200.

46. RETAILER TO KEEP RECORDS

(1) A licensed retailer shall -

(a) retain all delivery dockets and invoices relating to the receipt by him of a poison;

(b) enter in a register kept for that purpose, in a form approved by the Chief Medical Officer, details of each receipt and supply by him of a Schedule 1 or 7 substance; and

(c) where he supplies a Schedule 1 or 7 substance to fill a written order, retain the written order.

Penalty: $200.

(2) Where the supply of a Schedule 1 or 7 substance is conducted in the presence of a licensed retailer or a person acting on his behalf, the purchaser shall sign the register referred to in sub-section (1) next to the entry made in relation to that supply.

Penalty: $200.

47. PHARMACIST TO KEEP RECORDS

(1) Subject to sub-section (2), in addition to the records required to be kept by him under Parts VI and VII, a pharmacist shall -

(a) retain all delivery dockets or invoices relating to the receipt by him of a Schedule 1, 7 or 8 substance; and

(b) enter in a register kept for that purpose, in a form approved by the Chief Medical Officer, details of each supply by him of Schedule 1, 4, 7 or 8 substances.

Penalty: $200.

(2) The receipt or supply of a substance referred to in sub-section (1)(b) recorded in a prescription book or other form of record approved by the Chief Medical Officer is sufficient compliance with that sub-section.

48. MEDICAL PRACTITIONER, &c., TO KEEP RECORDS

A medical practitioner, dentist or veterinary surgeon shall -

(a) retain all delivery dockets or invoices relating to the receipt by him of a poison; and

(b) enter in a register kept for that purpose or in a form approved by the Chief Medical Officer, details of the supply or administration by him of a Schedule 4, 7 or 8 substance, including the reason for the supply or administration.

Penalty: $200.

49. AUTHORIZED PERSON TO KEEP RECORDS

A person authorized by or under this Act to possess and use a Schedule 4, 7 or 8 substance, other than a person obtaining that substance on the prescription of a medical practitioner, dentist or veterinary surgeon, shall -

(a) retain all delivery dockets or invoices relating to the receipt by him of that substance;

(b) enter in a register kept for that purpose, in a form approved by the Chief Medical Officer, details of the supply or administration by him of that substance; and

(c) where that substance is supplied or administered by him to fill a written prescription, retain the prescription.

Penalty: $200.

50. RETENTION OF RECORDS

A record, invoice, delivery docket, written order or prescription required by this Part to be kept or retained shall be retained for 2 years after the date of the last entry in the record in which it is recorded.

Penalty: $200.

PART X - STORAGE OF POISONS

51. STORAGE TO PREVENT PUBLIC ACCESS

The person in charge of premises in which a Schedule 1, 3, 4 or 7 substance is stored shall -

(a) ensure that the substance is stored in an area and in such a manner as to prevent unauthorized access to it; and

(b) take such measures as are reasonably necessary to prevent unauthorized access to that substance, whether or not the premises are open for business.

Penalty: $200.

52. STORAGE OF SCHEDULE 8 SUBSTANCES

(1) Subject to this section, a person who has in his possession a Schedule 8 substance, other than that supplied on the prescription of a medical practitioner, dentist or veterinary surgeon, shall, except when it is in actual use, keep that substance in a locked room, safe, cupboard or container of a type approved by the Chief Medical Officer.

Penalty: $200.

(2) A pharmacist who has in his possession a Schedule 8 substance shall store that substance in a safe which complies with the specifications the Chief Medical Officer, from time to time, determines.

Penalty: $200

(3) Where a Schedule 8 substance is kept for emergency purposes in the possession of a medical practitioner, dentist or veterinary surgeon, it is sufficient compliance with sub-section (1) if that substance is kept -

(a) in a locked bag in the possession of that person; or

(b) in a locked room or motor vehicle, the key of which is in the personal possession of that person.

PART XI - PESTICIDES AND OTHER SCHEDULE 7 SUBSTANCES

53. POSSESSION, &c., OF SCHEDULE 7 SUBSTANCES

(1) A person may apply to, and in a form approved by, the Chief Medical Officer or his delegate for authorization to possess and use a Schedule 7 substance.

(2) Subject to section 59, the Chief Medical Officer may authorize a person to possess and use a Schedule 7 substance which is intended for use for an agricultural, horticultural, pastoral or other purpose approved by the Chief Medical Officer, if he is satisfied that that person has sufficient reason to possess and use that substance.

54. SUPPLY OF PESTICIDES, &c.

(1) Subject to Parts II to VII inclusive, a person shall not supply to another person a Schedule 7 substance unless he is satisfied by sighting the authorization or licence, or by statutory declaration, of the other person, that -

(a) the other person is entitled under section 58 to possess and use the substance;

(b) the other person is authorized under section 53 to possess and use the substance; or

(c) in his opinion, the other person has a genuine agricultural, horticultural or pastoral use for that substance and has a reasonable understanding of how safely to use it.

Penalty: $1,000 or imprisonment for one year.

(2) A statutory declaration referred to in sub-section (1) shall be kept by the supplier with the records to which it relates required under Part IX to be kept by him and shall be retained for the period during which those records are required to be retained.

Penalty: $200.

55. APPLICATION FOR LICENCE

(1) A person may apply to the Chief Medical Officer for a licence to be a pest control operator.

(2) An application under sub-section (1) shall include -

(a) the full name and address of the applicant;

(b) the name and address of the applicant's employer, if any;

(c) full details of any Schedule 7 substance proposed to be used by the applicant and the purposes for which it is proposed to be used; and

(d) details of the applicant's experience and training in pest control procedures and the handling of poisons.

56. GRANT OF LICENCE

(1) Subject to this section, the Chief Medical Officer may grant to an applicant under section 55 a licence to be a pest control operator if he is satisfied, whether by examination or by such other means as he thinks fit, that the applicant has adequate knowledge of -

(a) the properties of the substances proposed to be used;

(b) the proper procedures for the safe storage, handling, application and disposal of the substances proposed to be used;

(c) the symptoms of poisoning by the substances proposed to be used and the correct first aid procedures to be applied in the case of such poisoning; and

(d) the provisions of this Act and the Regulations relating to substances used as or in pesticides.

(2) A licence under this section shall not be granted until the applicant has paid the prescribed fee.

57. RENEWAL OF LICENCE

A licence granted under section 56 shall remain in force for 12 months from the date on which it was granted and may be renewed from time to time for further periods of 12 months on application to the Chief Medical Officer, in a form approved by him, and on payment of the prescribed fee.

58. AUTHORITY TO POSSESS POISONOUS SUBSTANCES

A person licensed under section 55, or a person acting under the direct supervision of that person, may possess and use the Schedule 7 substances in respect of which the licence was granted.

59. MEDICAL EXAMINATION

(1) The Chief Medical Officer may require -

(a) an applicant under section 55;

(b) the holder of a licence granted or renewed under this Part; or

(c) a person who is employed by a person referred to in paragraph (b),

to undergo a medical examination and may, if the results of that medical examination indicate to the satisfaction of the Chief Medical Officer that the use or continued use of the substance used or proposed to be used constitutes a threat to the health of that person -

(d) refuse to grant or renew a licence granted under this Part;

(e) suspend for a specified period, a licence granted under this Part, or

(f) order in writing the employer of a person referred to in paragraph (c) to cease to employ that person in any capacity involving the handling of or exposure to such pesticides as are specified in the order.

(2) A person to whom an order under sub-section (1) is directed shall comply with and not contravene the order.

Penalty: $200.

PART XII - METHYLATED SPIRITS

60. ADDITIVES TO METHYLATED SPIRITS

The Chief Medical Officer may, by notice in the *Gazette*, require that methylated spirits manufactured in or brought into the Territory after a date specified in the notice, which is not designated by label to be for industrial purposes or for use by medical practitioners, dentists, veterinary surgeons or pharmacists in compounding medical preparations for external use, shall contain such additional substances, in such proportions, as is specified in the notice.

61. DRINKING OF METHYLATED SPIRITS

A person who drinks methylated spirits is guilty of an offence.

Penalty: Imprisonment for 3 months.

62. SUPPLY OF METHYLATED SPIRITS FOR DRINKING

A person who, having reasonable cause to believe that it is intended to be used for drinking purposes by the person to whom it is supplied or by another person, supplies methylated spirts to a person, is guilty of an offence.

Penalty: Imprisonment for 3 months.

63. POSSESSION, &c., OF METHYLATED SPIRITS REQUIRED TO BE ADULTERATED

(1) A person who supplies or has in his possession or under his control methylated spirits required under section 60 to contain an additional substance which does not contain that additional substance or contains that additional substance in a proportion less than that required under that section, is guilty of an offence.

Penalty: Imprisonment for 3 months.

(2) It is a defence to a charge for an offence against sub-section (1) (other than the offence of supplying) if the person charged satisfies the court that the methylated spirits in respect of which he is charged was brought or imported by him into the Territory from a place where the additional substance is not required by the law in force in that place to be added to methylated spirits or to be added in the proportion required under section 60, as the case may be, and that it was in the Territory for so short a time before the alleged offence was committed that the addition to it of the prescribed substance was not practicable in that time.

PART XIII - OFFENCES, PENALTIES, INVESTIGATIONS, &c.

64. POSSESSION AND ADMINISTRATION

Subject to this Act, a person who -

(a) uses or has in his possession, or attempts to obtain possession of, a prohibited drug or Schedule 8 substance;

(b) produces, prepares or manufactures a prohibited drug or Schedule 8 substance;

(c) supplies or administers to another person a prohibited drug or Schedule 8 substance; or

(d) has in his possession a prohibited drug or Schedule 8 substance for the purpose of supply or administration to another person,

is guilty of an offence.

65. USE, &c., PROHIBITED OR SUBJECT TO CONDITIONS

(1) Where the possession, use, production or manufacture in, or importation into, the Territory of a hazardous substance is prohibited under this Act, a person who possesses, uses, produces, manufactures or imports that hazardous substance in contravention of that prohibition is guilty of an offence.

Penalty: $10,000 or imprisonment for 5 years.

(2) Where the possession, use, production, manufacture, importation, supply or administration of a poison or hazardous substance is permitted by or under this Act subject to conditions, a person shall not possess, use produce, manufacture, import, supply or administer it except in accordance with those conditions.

Penalty: $2,000 or imprisonment for 2 years.

66. POSSESSION OF CANNABIS

(1) Subject to sections 69, 76 and 77, a person who uses, has in his possession, or attempts to obtain possession of, cannabis is guilty of an offence.

(2) A person who -

(a) produces, prepares or manufactures cannabis;

(b) supplies or administers cannabis to another person; or

(c) has cannabis in his possession for the purpose of supply or administration to another person,

is guilty of an offence.

(3) Where a person is charged with an offence of supplying or administering cannabis to another person contrary to sub-section (2)(b) and the court before which he is charged is satisfied that the offence charged is of a minor or trivial nature, it may, instead of committing that person for trial on indictment in respect of that alleged offence, determine the charge in a summary way in accordance with the *Justices Act* as though the maximum penalty for the offence charged does not, under this Act, exceed imprisonment for 10 years.

67. PRESUMPTION OF POSSESSION FOR SUPPLY

(1) A person who has in his possession a prohibited drug of a kind specified in column 1 of Schedule III in a quantity in excess of that specified in column 2 of that Schedule opposite that drug in column 1, shall be deemed to have that prohibited drug in his possession for the purpose of supply to another person, unless the contrary is proved.

(2) A person who has in his possession cannabis -

(a) in the form of a plant or part of a plant in a quantity in excess of 50 grams; or

(b) in the form of an extract, resin or tincture in a quantity in excess of 10 grams,

shall be deemed to have that cannabis in his possession for the purpose of supply to another person, unless the contrary is proved.

68. POSSESSION OF PROHIBITED PLANTS

(1) A person who knowingly grows, cultivates or has in his possession a plant from which a prohibited drug or Schedule 8 substance may be obtained shall be deemed to have that prohibited drug or Schedule 8 substance in his possession and to have it in his possession for the purpose of supply to another person, unless the contrary is proved.

(2) A person who knowingly grows, cultivates or has in his possession cannabis in plant form shall be deemed to have that cannabis in his possession for the purpose of supply to another person, unless the contrary is proved.

69. DEFENCE IN PROSECUTION

It is a defence to a charge for an offence of being in possession of a prohibited drug, Schedule 8 substance or cannabis if the person charged proves that he had a reasonable excuse for being in possession of that prohibited drug, Schedule 8 substance or cannabis.

70. OWNER OR OCCUPIER OF PREMISES

(1) The owner or occupier of premises who knowingly allows a prohibited drug or Schedule 8 substance -

(a) to be produced, prepared or manufactured by another person; or

(b) to be used or kept by another person,

on those premises is guilty of an offence.

(2) The owner or occupier of premises who knowingly allows cannabis to be kept by another person on those premises is guilty of an offence.

(3) The owner or occupier of premises who knowingly allows cannabis to be grown, cultivated, produced, prepared or manufactured by another person on those premises is guilty of an indictable offence.

71. EXEMPTION

(1) Notwithstanding anything contained in this Act, a person who -

(a) is in possession of a poison which has been supplied to that person by or on the prescription of a medical practitioner, dentist or veterinary surgeon; or

(b) administers a poison to another person in accordance with the directions of a medical practitioner or a dentist,

is not guilty of an offence under this Act.

(2) In this section "medical practitioner" includes a person who is entitled to practise as a medical practitioner under a law in force in a State or another Territory of the Commonwealth.

72. SEARCH WARRANTS

(1) Where it is made to appear to a Justice, by application on oath, that there are reasonable grounds for believing -

(a) that there is in or on premises or a vehicle or vessel a prohibited drug, Schedule 8 substance or cannabis; or

(b) that a prohibited drug, Schedule 8 substance or cannabis may be concealed on a person or on or in property in the immediate control of a person,

that Justice may issue a warrant authorizing a member of the Police Force named in the warrant, with such assistance as he thinks necessary, to search -

(c) in a case referred to in paragraph (a) - the premises, vehicle or vessel; and

(d) in a case referred to in paragraph (b) -

(i) the body of that person;

(ii) the clothing worn by that person; or

(iii) the property in the immediate control of that person.

(2) Under this section -

(a) an application for a warrant and a submission concerning an application may be made;

(b) information concerning an application may be furnished; and

(c) an oath may be administered,

in whole or in part, by telephone, telex, radio or other similar means.

(3) A warrant shall -

(a) if it is issued under sub-section (1)(c) - be substantially in accordance with the form in Schedule V; and

(b) if it is issued under sub-section (1)(d) - be substantially in accordance with the form in Schedule VI and shall remain in force for such period as the Justice issuing it specifies in the warrant.

(4) Where a warrant is issued by a Justice as the result of an action taken under or in pursuance of sub-section (2), the Justice shall send the warrant, within 7 days after its issue, to the Commissioner of the Police Force.

(5) Where it is necessary for a member of the Police Force to satisfy a person that a warrant under this section was issued authorizing that member to conduct a search and, for reasonable cause, that member cannot at the time produce the warrant, he may produce a copy of the warrant completed and endorsed in accordance with sub-section (6) and that production shall be deemed to be a production of the warrant.

(6) To comply with sub-section (5), a member of the Police Force -

(a) shall complete a form of warrant substantially in the terms of the warrant issued by the Justice; and

(b) shall write on that form of warrant a statement that a warrant in those terms was issued giving -

(i) the name of the Justice who issued the warrant; and

(ii) the date, time and place on and at which the warrant was issued.

73. SEARCHING VEHICLES, &c.

A member of the Police Force may stop, search and detain -

(a) a vessel, vehicle, caravan, trailer or other conveyance in which that member has reason to suspect that a prohibited drug, Schedule 8 substance or cannabis may be found; or

(b) a person in a public place whom that member has reason to suspect has in his possession, or is in any way conveying, a prohibited drug, Schedule 8 substance or cannabis.

74. USE OF REASONABLE FORCE

The power to search conferred by section 73 or under a warrant issued under section 72 authorizes a member of the Police Force -

(a) to use such reasonable force as is necessary to break into, enter and search the premises or conveyance to be searched;

(b) to use such reasonable force as is necessary to open any cupboard, drawer, chest, trunk, box, package or other receptacle, whether a fixture or not, found on or in the premises or in the conveyance; and

(c) to search a person found on or in the premises or the conveyance being searched.

75. SEARCH OF FEMALES

(1) A search of a female under this Act shall be carried out only -

(a) by a female member of the Police Force;

(b) by a medical practitioner authorized by a member of the Police Force to carry out that search; or

(c) where there is neither a female member of the Police Force nor a medical practitioner available - by a female person authorized by a member of the Police Force to carry out that search.

(2) Where a medical practitioner or a female person is authorized under sub-section (1) to carry out a search of a female, the medical practitioner or female person

carrying out the search has, for the purposes of that search, the same powers, and is subject to the same protection, as a member of the Police Force.

76. POSSESSION BY MEMBER OF POLICE FORCE

(1) Notwithstanding anything contained in this Act, the possession of a prohibited drug, Schedule 8 substance or cannabis by a member of the Police Force, an inspector or a person authorized by a member of the Police Force to have that prohibited drug, Schedule 8 substance or cannabis in his possession is not an offence if that prohibited drug, Schedule 8 substance or cannabis -

(a) was seized or obtained in -

(i) the execution of the duties; or

(ii) the exercise of the powers,

under this Act or any other law in force in the Territory of that member, inspector or other person;

(b) is in his possession pending the institution and hearing of proceedings for an offence against this Act or that other law; or

(c) is in his possession for a purpose associated with the administration of this Act.

(2) A prohibited drug, Schedule 8 substance or cannabis shall be deemed to be in the possession of a person for a purpose associated with the administration of this Act if it is held by him for analysis for the purpose of proceedings for an offence against this Act or of any other law in force in the Territory or of qualifying him to give evidence at the hearing of those proceedings.

(3) Where proceedings for an offence against this Act have commenced, a member of the Police Force who has obtained a prohibited drug, Schedule 8 substance or cannabis and a person who has obtained a prohibited drug, Schedule 8 substance or cannabis at the request in writing of a member of the Police Force shall not, by reason of that circumstance, be taken to be an accomplice in that offence or guilty of an offence against this Act, nor shall the evidence of that member of the Police Force or of that person be taken, on the hearing of the proceedings, to be the evidence of an accomplice.

77. SEIZURE OF SUBSTANCES

(1) A member of the Police Force may seize -

(a) a substance found in the possession of a person or as the result of a search, being a substance that that member has reason to suspect is a prohibited drug, Schedule 8 substance or cannabis;

(b) money, a valuable security or other thing -

(i) found in the possession of a person or at his disposal; or

(ii) found as the result of a search,

being money, a valuable security or thing that that member has reason to suspect was received or acquired by a person directly or indirectly as or from the proceeds or part of the proceeds of the supply of a prohibited drug, Schedule 8 substance or cannabis;

(c) an acknowledgement, note or other thing -

(i) found in the possession of a person or at his disposal; or

(ii) found as the result of a search,

being an acknowledgement, note or thing that that member has reason to suspect -

(iii) entitles a person to receive; or

(iv) is evidence that a person is entitled to receive,

money or money's worth that is the proceeds or part of the proceeds of the supply of a prohibited drug, Schedule 8 substance or cannabis;

(d) a thing found in the possession of a person as the result of a search, being a thing that that member has reason to believe affords evidence of the commission of an offence against this Act; or

(e) where a person is apprehended for an offence against this Act, an article -

(i) found in the possession of that person; or

(ii) found as the result of a search,

being an article that is of a type used in the production, preparation, manufacture, consumption, smoking or administration of a prohibited drug, Schedule 8 substance or cannabis.

(2) In this section "search" means a search in pursuance of a power conferred by or under this Act or any other law in force in the Territory.

78. USE OF DIAMORPHINE HYDROCHLORIDE

(1) The Chief Medical Officer may, subject to sub-section (2), authorize -

(a) the possession;

(b) the production, preparation or manufacture;

(c) the supply to another person;

(d) the administering to another person; or

(e) the use,

of diamorphine hydrochloride and, notwithstanding anything contained elsewhere in this Act, a person so authorized may possess, produce, prepare, manufacture, supply, administer or use, as the case may be, that drug in accordance with that authorization.

(2) The Chief Medical Officer shall not authorize -

(a) the possession, production, preparation or manufacture of diamorphine hydrochloride unless for the purpose of treating a terminally ill person; or

(b) the supply to another person, the administering to another person or the use by a person of diamorphine hydrochloride unless he is satisfied that the person who is to use or to be treated with the drug is -

(i) terminally ill; and

(ii) suffering such pain that the use or administration of the drug is warranted in the circumstances.

(3) An authorization referred to in sub-section (1) shall -

(a) be in writing;

(b) be signed by the Chief Medical Officer;

(c) name the person to whom the authorization is given; and

(d) where the authorization relates to the use or administration of diamorphine hydrochloride, name the person who is to use the drug or to whom it is to be administered.

79. FORFEITURE OF DRUGS, &c.

(1) On the conviction of a person for an offence against this Act, any prohibited drug, Schedule 8 substance or cannabis in respect of which the conviction is made is forfeited to the Crown.

(2) Where a person is convicted of an offence against this Act, the court by which he is convicted may order that any money, money's worth, valuable security, acknowledgement, note or other thing that relates to that offence be forfeited to the Crown.

(3) Where any moneys, money's worth, valuable security, acknowledgement, note or other thing that is forfeited under sub-section (2) is in the possession or control of, or held at the direction of, a person other than the convicted person, that other person shall, upon production to him of a copy of the order made under that sub-section, immediately pay the moneys or deliver the money's worth, valuable security, acknowledgement, note or other thing to the Crown.

Penalty: $1,000 or imprisonment for 6 months.

(4) Upon payment or delivery being made in accordance with sub-section (3), the liability to the convicted person or to any other person of the person making the payment or delivery is, to the extent of that payment or delivery, discharged.

(5) A thing forfeited to the Crown under this section shall be dealt with in such manner as the Administrator directs.

(6) Where a Judge or a Justice makes an order under sub-section (2), the Judge or the Justice shall make and sign a minute or memorandum of the order.

(7) A minute or memorandum referred to in sub-section (6) may be registered in a court of competent jurisdiction.

(8) Upon registration under sub-section (7), the minute or memorandum becomes a record of the court with the same force and effect as a judgment of that court, and the like proceedings (including proceedings in bankruptcy) may be taken upon the minute or memorandum as if the order had been a judgment of the court in favour of the Crown as

plaintiff and the owner of the forfeited money, money's worth, valuable security, acknowledgement, note or other thing against the convicted person as defendant.

(9) For the purposes of this section, any money, money's worth, valuable security, acknowledgement, note or other thing shall be taken to relate to an offence -

(a) if it is an article referred to in section 77(1)(b) or (c);

(b) if it was used in the commission of an offence against this Act;

(c) if it was received or acquired directly or indirectly as or from the proceeds or part of the proceeds of the sale of a prohibited drug, Schedule 8 substance or cannabis; or

(d) if it entitles a person, or is evidence that a person is entitled, to receive money or money's worth as the proceeds or part of the proceeds of the sale of a prohibited drug, Schedule 8 substance or cannabis,

whether or not the money, money's worth, valuable security, acknowledgement, note or other thing is or was at any time owned by or in the possession or control of the convicted person.

(10) Where a person is charged with an offence against this Act, any other person claiming ownership of or an interest in any money, money's worth, valuable security, acknowledgement, note or other thing that may be the subject of an order under this section may, by leave of the court at the trial of the person charged, appear and show cause why that money, money's worth, valuable security, acknowledgement, note or other thing should not be forfeited.

(11) Upon hearing a person under sub-section (10), the court may order that the money, money's worth, valuable security, acknowledge ment, note or other thing be released or returned to that or any other person.

(12) Where an order is made under sub-section (2) after a person has appeared before the court by leave of the court under sub-section (10), that person may appeal from the order of the court as if he were a defendant.

80. RETURN OF SEIZED ITEMS

(1) Where a thing is seized under this Act and no proceedings are instituted for an offence relating to the thing seized, the Commissioner of the Police Force -

(a) shall return the thing seized to the person whom he believes, on reasonable grounds, is its owner and is entitled by law to have it in his possession; or

(b) shall, by notice in writing, where he is not satisfied as to whom that thing should be returned, require the person from whom the thing was seized, or any person appearing to the Commissioner to be the likely owner of that thing, to claim delivery of that thing.

(2) If no claim is made within 21 days after the date of service of a notice in writing under sub-section (1)(b), or after reasonable inquiry the person to whom the notice is addressed cannot be found, the thing seized is forfeited to the Crown and shall be disposed of in the manner directed by the Administrator.

(3) Where a person served with a notice under sub-section (1)(b) makes a claim for the delivery to him of a thing seized or, in the opinion of the Commissioner of the Police Force, the owner is not entitled by law to have the thing seized in his possession, the Commissioner shall refer the claim or question to a court of summary jurisdiction and the court may deal with the matter as if in either case it was a claim under section 130B of the *Justices Act* by a claimant of property.

81. PENALTIES

(1) Subject to sub-section (2), a person who is guilty of an offence against this Act is liable -

(a) in the case of an offence against section 64(a) or 70(1)(b) -

(i) for a first offence - to a fine of $5,000;

(ii) for a second offence - to imprisonment for 5 years; and

(iii) for a third or subsequent offence - to imprisonment for 10 years;

(b) in the case of an offence against section 64(b), (c) or (d), 66(2) or 70(1)(a) or (3) -

(i) for a first offence - to imprisonment for 7 years;

(ii) for a second offence - to imprisonment for 15 years; and

(iii) for a third or subsequent offence - to imprisonment for 25 years; and

(c) in the case of an offence against section 66(1) or 70(2) -

(i) for a first offence - to a fine of $500;

(ii) for a second offence - to a fine of $1,000; and

(iii) for a third or subsequent offence - to a fine of $2,000.

(2) Where a person had been convicted for an offence or offences against a provision of a law of a State, the Commonwealth or another Territory of the Commonwealth (whether committed before or after the commencement of this Act) which provision, in the opinion of the Court, was in substance equivalent to the provision of this Act for the commission of an offence against which he has been found guilty by the Court, that previous offence or those previous offences shall, for the purposes of sub-section (1), be deemed to have been committed against the provision of this Act.

82. PROOF OF EXCEPTIONS

(1) Where a person is charged with an offence, an exception relating to a substance the subject of the charge need not be specified or negatived in the information or the indictment.

(2) The burden of proof of an exception referred to in sub-section (1) is on the person alleging it.

83. APPLICABILITY OF *JUSTICES ACT*

(1) Section 120 of the *Justices Act* does not apply to or in relation to an offence against section 64(a) or 70(1)(b).

(2) Division 2 of Part V of the *Justices Act* does not apply to or in relation to an offence against section 64(b), (c) or (d), 66(2) or 70(1)(a) or (3).

(3) Where a court decides, under section 66(3), to determine a matter in a summary way, sub-section (2) shall be read as though that sub-section had no application to section 66(2)(b).

84. CERTIFICATE OF ANALYSIS

(1) Subject to sub-section (2), in proceedings for an offence against this Act a certificate purporting to be signed by a person who claims in the certificate that he carried out a scientific analysis or examination -

(a) setting out particulars of his qualifications to carry out that analysis or examination;

(b) identifying the thing analysed or examined by him; and

(c) giving particulars concerning the analysis or examination that he carried out and stating the conclusions at which he arrived,

is evidence of the matters stated in that certificate.

(2) A certificate may not be tendered in pursuance of sub-section (1) without the consent of the person charged with the offence -

(a) unless, at least 7 days before the certificate is tendered, the person tendering the certificate serves upon the person charged -

(i) a copy of the certificate; and

(ii) a notice in writing drawing the attention of the person charged to this section, informing him that it is proposed to tender the certificate in evidence in the proceedings and furnishing the name of a person (therein called "the prosecutor") who will accept service of notices and an address for service; or

(b) if, within 4 days after being served with a certificate and notice under paragraph (a), the person charged serves on the person referred to in paragraph (a)(ii) a notice in writing that the person charged objects to the certificate being given in evidence.

85. ORDER FOR COSTS, &c.

Where a scientific analysis or examination has been carried out for the purpose of proceedings for an offence against this Act, the court may, in addition to any other order as to costs, make such order as it thinks fit -

(a) as to the payment of the expenses of and incidental to the analysis or examination; and

(b) where the person charged has served a notice of objection under section 84(2)(b) - as to the payment of the expenses of and incidental to the attendance at court of the person who carried out the analysis or examination.

86. ORDER OF INSPECTORS

A person ordered by an inspector to withdraw from supply a hazardous substance which is not packed or labelled in accordance with the requirements of this Act, the Regulations or the *Containers for Hazardous Substances Act* shall comply with that order.

Penalty: $200 or imprisonment for 3 months.

87. OBSTRUCTION OF POLICE OR INSPECTOR

A person shall not obstruct or hinder a member of the Police Force or an inspector in the performance of his duties under, or the execution of the powers vested in him by, this Act.

Penalty: $500 or imprisonment for 6 months.

88. POWER OF POLICE

The provisions of this Part relating to the power of a member of the Police Force are in addition to, and not in derogation of, any other power he may have under this Act or any other law in force in the Territory.

PART XIV - MISCELLANEOUS

89. CONTROL OF CERTAIN SUBSTANCES

The Minister may, by notice in the *Gazette*, prohibit -

(a) the possession or use in;

(b) the production or manufacture in; or

(c) the importation into,

the Territory of a poison or hazardous substance, or permit that possession, use, production, manufacture or importation subject to such conditions as to its transportation, storage, packaging, labelling, use or otherwise as he thinks fit.

90. MINISTER MAY AMEND SCHEDULES

(1) Subject to sub-section (2), the Minister may, by notice in the *Gazette*, amend a schedule in Part B of the schedules to this Act.

(2) The Minister shall not amend a schedule referred to in sub-section (1) unless he is satisfied that, by so doing, the schedule will comply with the recommendations for the time being of the National Health and Medical

Research Council established by an order made under section 9 of the *National Health Act* 1953 of the Commonwealth.

(3) A notice under sub-section (1) shall take effect from the date of its notification in the *Gazette* or, where a later date is provided for in the notice, from the date so provided, and shall have effect as if it were an Act made by the Legislative Assembly.

91. MINISTER MAY PRESCRIBE FEES

The Minister may, by notice in the *Gazette*, prescribe the fees payable in respect of a registration, licence, authorization and other forms of authority granted or issued under this Act.

92. REGULATIONS

(1) The Administrator may make regulations, not inconsistent with this Act, prescribing all matters required or permitted by this Act to be prescribed, or necessary or convenient to be prescribed for carrying out or giving effect to this Act.

(2) Without limiting the generality of sub-section (1), the Regulations may prescribe -

(a) the standards relating to, the precautions to be taken in, and the manner of, handling, transporting, packaging, labelling and disposal of poisons and hazardous substances; and

(b) penalties, not exceeding a fine of $2,000, for breaches of the Regulations.

THE SCHEDULES

Part A

SCHEDULE I

Section 3

ACTS AND ORDINANCES REPEALED

Short title	Number and year
Dangerous Drugs Ordinance 1977	No. 59, 1977
Dangerous Drugs Ordinance 1978	No. 71, 1978
Dangerous Drugs Act (No. 2) 1978	No. 99, 1978
Dangerous Drugs Act 1980	No. 29, 1980
Methylated Spirit Ordinance 1936	No. 15, 1936
Methylated Spirit Ordinance 1938	No. 7, 1938
Methylated Spirit Ordinance 1952	No. 44, 1952
Methylated Spirit Ordinance 1962	No. 29, 1962
Methylated Spirit Ordinance 1964	No. 42, 1964
Poisons Ordinance 1924	No. 6, 1924
Poisons Ordinance 1928	No. 29, 1928
Poisons Ordinance 1930	No. 6, 1930
Poisons Ordinance 1958	No. 15, 1958
Poisons Ordinance 1964	No. 43, 1964
Poisons Ordinance 1968	No. 11, 1968
Poisons Ordinance 1969	No. 4, 1969
Poisons Ordinance 1970	No. 77, 1970
Poisons Ordinance 1977	No. 58, 1977
Poisons Act 1978	No. 124, 1978
Poisons Act 1980	No. 30, 1980
Prohibited Drugs Ordinance 1977	No. 60, 1977
Prohibited Drugs Ordinance 1978	No. 72, 1978
Prohibited Drugs Act 1980	No. 31, 1980
Prohibited Drugs (Amendment) Act (No. 2) 1980	No. 18, 1981

SCHEDULE II

Section 6(1)

PROHIBITED DRUGS

Acetorphine (0^3-acetyl-7, 8 dihydro-7a (1(R)-hydroxy-1-methyl-butyl)-0^6-methyl-6, 14-endoetheno-morphine)
Allyl isopropyl acetyl urea
2-amino-1(2,5-dimethoxy-4-methyl)phenylpropane (STP, DOM)
Aminophenazone and derivatives therefrom for human therapeutic use
Amygdalin
Bithionol for human therapeutic use
Buclosamide
Bufotenine
Buniodyl sodium
Calamus for human therapeutic use
Cannabis and cannabis resin and extracts or tinctures of cannabis
Desomorphine
Diamorphine (Heroin)
3-(1,2-Dimethylheptyl)-1-hydroxy-7,8,9,10-tetrahydro-6,-6,9-trimethyl-6H-dibenzo (b,d) pyran (DMPH)
Dulcin
N-Ethyl-1-phencyclohexylamine (PCE)
Etorphine (7,8-dihydro-7a(1(R)-hydroxy-1-methyl-butyl)-0^6-methyl-6, 14-endoethenomorphine)
Halogenated dibenzodioxins and dibenzofurans except as a contaminant in proportions not exceeding those specified by relevant Commonwealth, State or Territory legislation
3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo (b,d) pyran (parahexyl)
Ketobemidone
Lysergide
Mescaline, 2,5-dimethoxy-4-methylamphetamine, and other substances structurally derived from methoxyphenylethylamine having hallucinogenic properties
Methyl cinchophen
N,N-diethyltryptamine
N,N-dimethyltryptamine
Oxyphenisatin and its acetyl derivatives for human therapeutic use
1-(1-Phencyclohexyl)pyrrolidine (PHP or PCPY)
Psilocin
Psilocybin
Tetrahydrocannabinols and 3- and 4'-alkyl homologues, including DMPH and PARAHEXYL, within one of those structural designations
1-(1-(2-Thienyl)cyclohexyl)piperidine (TCP)
1,1,1,-Trichloroethane in aerosols for therapeutic use
Triparanol

SCHEDULE III

Section 66(1)

MINIMUM QUANTITIES OF PROHIBITED DRUGS

Prohibited drug	Quantity
2-Amino-1(2,5-dimethoxy-4-methyl) phenyl-propane (STP, DOM)	0.5 grams
Bufotenine	0.5 grams
Desomorphine	0.5 grams
Diamorphine (heroin)	0.5 grams
3-(1,2 Dimethylheptyl)-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-$^{-6}$H-dibenzo (b,d) pyran (DMPH)	0.5 grams
3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl^{-6}H-dibenzo pyran(parahexyl)	0.5 grams
Ketobemidone	0.5 grams
Lysergide, lysergic acid, lysergic acid diethylamide (LSD), or other amides structurally derived from lysergic acid	0.002 grams
Mescaline	7.0 grams
Methylenedioxy amphetamine (MDA)	0.5 grams
N,N-Diethyltryptamine (DET)	0.5 grams
N,N-Dimethyltryptamine (DMT)	0.5 grams
Psilocybin	0.1 grams
Psilocine	0.1 grams
Psilotsin and other substances structurally derived from 3-(2 aminoethyl)-indole	0.1 grams
Tetrahydrocannabinols	2.0 grams

SCHEDULE IV

Section 6(3)

EXEMPTED SUBSTANCES AND THINGS

Acetofenate
Acinitrazole
Acrylonitrile
Agglutinating preparations used in human pregnancy tests
Albendazole
Aliphatic alcohols, C_6-C_{10}
Alum
Aluminium silicate
Aluminium tris (ethylphosphonate) when intended for use as a fungicide on ornamental plants
Ammonium chloride
Ammonium ethyl carbamoyl phosphonate
Ammonium phosphate
Ammonium sulphamate
Ammonium sulphate
Ammonium thiosulphate
Amprolium
Amyl acetate
Amyl alcohol
Amyl lactate
Anilazine
Anthraquinone
Anticoagulent substances in preparations for external application
Arnica
Aspartic acid
Asulam
Atrazine
Aziprotryne
Bacillus thuringiensis
Barium sulphate
Benfluralin
Benomyl
Benzalkonium chloride
Benzoic acid
Benzyl alcohol
Betaine hydrochloride
6-Benzyladenine
1-(Biphenyl-4-yloxy-3,3-dimethyl-1-(1,2,4-triazol-1-yl) butan-2-OL(bitertanol)
Bisacodyl
Biuret
Boro-tannic complex
Bromacil
Bromopropylate
Bromsalans
Brucine in concentrations of 0.02% or less for the denaturation of alcohol
Bucarpolate
Bupirimate

Buquinolate
Butachlor
Butadiene furfural copolymer
Butopyronoxyl
Butoxypolypropylene glycol
Butralin
Butyl acetate
Butyl alcohol
n-Butyl butyrate
Butyl ethers
n-Butyl lactate
Butyrolactone
Calcium carbide
Calcium chloride
Calcium oxide
Calcium polysulphide
Caprylic acid diethylamide
Captan
Carbendazim
Carbetamide
Carbon monoxide
Carboxin
Cetyl alcohol
Chloraniformethan
Chloranil
Chlorbenside
Chlorbromuron
Chlorfensulphide
Chlorflurenol
Chlorhexidine
Chlorobenzene
Chloroneb
Chloroxylenols
Chloroxuron
Chlorpropham
Clorthal-dimethyl
Citronella oil
Clenpirin
Clioxanide
Cobalt naphthenate
Colocynth
Copper salts except copper sulphate as such
Cyclamic acid as permitted in the Standard for Artificial Sweetening Substances published by the National Health and Medical Research Council
Cyclohexane
Cyclohexanol
Cyclohexanol acetate
Cyclohexanone
Cycloprate
Daminozide
Decoquinate
Decyl alcohol
Derris dust
Diacetone alcohol
Diaveridine

Dibutylphthalate
Dichlobenil
1,1-Dichloro-2.2-bis (p-ethylphenyl)-ethane
N-3,5-Dichlorophenyl)-1, 2-dimethylcyclopropane carboximide
Dichlorodifluoromethane
Dichlorotetrafluoroethane
Diethanolamine
Diethyl carbonate
Diethyl ketone
Diethyl toluamide
1,1-Difluoro-1-chloroethane
Di-isobutyl carbinol
Di-ispropylamine dichloroacetate except for human therapeutic use
Dikegulac-sodium
Dimethametryn
Dimethicone
Dimethyl cyclohexanol
Dimethyl phthalate
Dimethyl sulphate
3,4-Dinitro-o-toluamide
Dinsed
Dioctyl sodium sulphosuccinate
Dipentene
Di-h-propyl iso-cinchomerate
Diuron
Dodecanol
2,2-DPA
Edta
Emetine in preparations containing 0.2% or less
Ethidimuron
Ethopabate
Ethyl acetate
Ethyl alcohol
Ethyl amyl ketone
Ethyl butyl acetate
Ethyl butyrate
Ethyl formate
Ethyl hexanediol
2-Ethyl hexanol
Ethylidene chloride
Ethyl lactate
Ethyl methacrylate
Ethyl silicate
Explosives
Fenantel
Fenbendazole
Fenfuram
Fenuron
Ferric sulphate
Fosamine
Fluometuron
Fluorocarbon propellants in aerosols
Folpet
[[[2-[(2-Furanyl-methylene) amino] phenyl] amino] thioxomethyl]-carbamate

Furfural
Furfuryl alcohol
Gentian violet
Gibberellic acid
Glazed pottery
Glycophene
Glyodin
Glyphosine
D-Glucuronolactone
Heliothis nuclear polyhedrosis virus
Heptyl alcohol
Hexachloroethane
Hexane
Hexanol
Hexyl acetate
Hexyl alcohols
Hydrogen phosphide
Hydrogen sulphide
2-Hydroxyethyl-N-octyl sulphide
Imidocarb
Indole butyric acid
Iodised oil injection
Iodoform
Iprodione
Isoamyl acetate
Isobornyl thiocyanoacetate
Isophorone
Isopropyl alcohol
Isopropyl benzoate
Isopropyl(E.E)-11-methoxy-3-7, 11-trimethyl-2,4-dodecadienoate
Karbutilate
Lauryl alcohol
Lead, metallic
Lenacil
Lime sulphur
Linuron
Lobelia in preparation for smoking or burning
Lubricants, unless specified in any of the Schedules in Part B
Maleic hydrazide
Manganese naphthenate
Matches
Mefluidide
Meglumine iothalamate
Menthol
Mercuric chloride in batteries
Mercury, "metallic", in scientific instruments
Mesityl oxide
Methenamine hiprurate
3-Methoxy butanol
Methoxy hexanone
Methyl acetate
Methyl amyl alcohol
Methyl benzoquate
Methyl cyclohexanol

Methyl cyclohexanol acetate
Methyl cyclohexanone
Methylene chloride when used in aerosols
2-Methylfur-3-anilide
Methyl p-hydroxy benzoate
Methyl lactate
2-Methyl-2,4-pentanediol
Methyl polysiloxane
Metichlorpindol
Metobromuron
Metoxuron
MGK 264
Mineral oil
Monochlorcarvacrol
Monochlorobenzene
Monoethanolamine
Monuron
Morantel
Motor fuels, other than those containing methyl alcohol, unless specified in the Schedules in Part B
Naphthyl acetamide
Napropamide
Neburon
Nicarbazine
Nifursol
Nitralin
Nitrilotriacetic acid
Nitromethane
Nitrothal-isopropyl
Nitrovin
Noruron
Octa-bicycloheptane dicarboximide
Octyl acetates
Octyl alcohols
Orthophenyl phenol
Oxibendazole
Paints as defined in the Uniform Paint Standard
Paper
Pelargonic acid
Pentanochlor
Pentachloro-2-chloromethylsulfonamide diphenylether
Permethrin
Petrol: (i) in preparations containing 25% or less; or
(ii) in containers of more than 20 litres
Petroleum oils
Phenmedipham
Phenothiazine
Phenothrin
d-Phenothrin
Photographic paper and film
Phthalthrin
Picloram
n-Picoline
Pinene
Pine oils
Piperazine
Piperonyl butoxide

Piprotol
Poloxalene
Potassium aluminium silicate
Praziquantel
Pregnenolone for topical use
Propazine
Propyl acetates
Propyl alcohols
Propylene glycol
Propylene oxide
Propyl gallate
Propyl-N[3-(dimethylamino) propyl] carbamate
Propyzamide
Protein hydrolysate
Quassia infusion
Red squill
Rodenidine
Saccharin
Selenium, metallic
Soduron
Simazine
Soap barb
Sodium carbonate
Sodium iothalamate
Sodium nitrate
Stramonium in preparations for smoking or burning
Sucralfate
Sulphated polysaccharides
Sulphoxide
Surfactants - anionic, nonionic
Swentinogen
Tannic acid
Terbacil
Terephthatic acid
Tetrahydrofuran
Tetrahydrofurfuryl acetate
Tetrahydrofurfuryl alcohol
Tetramethrin
Tetrasul
Thiabendazole
Thidiazuron
Thiophanate
Thiophanate - methyl
Thioxolone
Timber and wallboard
Tobacco
Trichlorofluoromethane
(Z)-9-Tricosene
Triethanolamine
Triethylene glycol
Trifluralin
Triforine
Urea
Vaccines, sera, toxoids, antitoxins and antigens other than live virus vaccines except for human parenteral use
Vinclozolin

Vinyl ether except when used for the induction of inhalation anaesthesia
Vitamin K
Vitreous enamels
Zanthophyll
Zinc naphthenate

SCHEDULE V

Section 72(3)(a)

Poisons and Dangerous Drugs Act

SEARCH WARRANT

To:.....,
(full name)
a member of the Police Force of the Northern Territory.

WHEREAS, on an application on oath under the *Poisons and Dangerous Drugs Act*, in relation to premises at.....
.....
(give address or otherwise identify premises)
or a vehicle.....
(identify vehicle)
or a vessel.....
(identify vessel)

I,.....
(full name)
a Justice within the meaning of that expression in that Act, am satisfied -

(a) that there is reasonable ground for believing that there is on or in those premises, or that vehicle or that vessel, prohibited drugs, Schedule 8 substances or cannabis; and

(b) that the issue of a warrant is reasonably required for the purposes of that Act:

YOU ARE HEREBY AUTHORIZED, with such assistance as you think necessary, to enter those premises, or that vehicle or that vessel, during the hours of . am/pm (or at any time), if necessary by force, for the purpose of exercising the powers of a member of the Police Force under that Act, namely to search those premises, or that vehicle or that vessel, and -

(c) to use such reasonable force as is necessary to open any cupboard, drawer, chest, trunk, box, package or other receptacle, whether a fixture or not, found on or in those premises, or that vehicle or that vessel;

(d) to seize -

(i) any substance found in the possession of a person or as the result of the search which you have reason to suspect is a prohibited drug, Schedule 8 substance or cannabis;

(ii) any money or valuable security found as a result of the search and suspected of being the proceeds of a sale of prohibited drugs, Schedule 8 substances or cannabis; or

(iii) any article found as a result of the search, being an article of a type used in the production, preparation, manufacture, consumption, smoking or administration of prohibited drugs, Schedule 8 substances or cannabis;

(e) to search any person found on or in those premises, or that vehicle or that vessel; and

(f) to do or perform such other acts as that Act permits.

AND for so doing, this shall be your sufficient warrant.

The authority granted by this warrant expires on / / .

Issued at o'clock in the noon
this day of , 19 .

Justice

SCHEDULE VI

Section 72(3)(b)

Poisons and Dangerous Drugs Act

SEARCH WARRANT

To:.....,
(full name)
a member of the Police Force of the Northern Territory.

WHEREAS, on an application on oath under the *Poisons and Dangerous Drugs Act*, in relation to.....
(full name)
of.....
(address)
(in this warrant called "the person named")

I,.....
(full name)
a Justice within the meaning of that expression in that Act, am satisfied, by information -

(a) that there is reasonable ground for believing that a prohibited drug, Schedule 8 substance or cannabis -

(i) is concealed on the person named; or

(ii) is concealed on or in property in the immediate control of the person named; and

(b) that the issue of a warrant is reasonably required for the purposes of that Act:

YOU ARE HEREBY AUTHORIZED, with such assistance as you think necessary -

(a) to use such reasonable force as is necessary to search -

(i) the body of the person named;

(ii) the clothing worn by the person named; and

(iii) property in the immediate possession of the person named, namely:

.....;
(describe the property to be searched)

(b) to seize -

(i) any substance found as the result of the search which you have reason to suspect is a prohibited drug, Schedule 8 substance or cannabis reasonably suspected of being a thing connected with an offence;

(ii) any money or valuable security found as a result of the search and suspected of being the proceeds of supply of prohibited drugs, Schedule 8 substances or cannabis; or

(iii) any article found as a result of the search and being an article of a type used in the production, preparation, manufacture, consumption, smoking or administration of prohibited drugs, Schedule 8 substances or cannabis; and

(c) to do or perform such other acts as that Act permits.

AND for so doing, this shall be your sufficient warrant.

The authority granted by this warrant expires on / / .

Issued at o'clock in the noon
this day of , 19 .

Justice

PART B

SCHEDULE 1

Substances which are extremely dangerous to human life

Aconite (root of aconitum napellus)
Antimony, compounds of, except antimony chlorides in polishes
Atropine except:
(a) when included in Schedule 2; or
(b) atropine methonitrate
Belladonna herb except in preparations containing 0.25% or less of the alkaloids of belladonna calculated as hyoscyamine
Bromine (excluding its salts and derivatives)
Brucine except when used in concentrations of 0.02% or less for the denaturation of alcohol
Coniine
Cotarnine
Croton oil
Cyanides - see hydrocyanic acid
Homatropine except when included in Schedule 2
Hydrocyanic acid for therapeutic use except when included in Schedule 2
Hyoscine except:
(i) when included in Schedule 2; or
(ii) hyoscine butylbromide
Hyoscyamine except when included in Schedule 2
Hyoscyamus except in preparations containing 0.25% or less of the alkaloids of hyoscyamus calculated as hyoscyamine
Lobelia except:
(i) in preparations for smoking or burning; or
(ii) when included in Schedule 2
Mercuric chloride except:
(a) in batteries; or
(b) when included in Schedule 2 or 7.
Mercuric iodide except when included in Schedule 2 or 6
Mercuric nitrate except when included in Schedule 2
Mercuric potassium iodide except when included in Schedule 2
Mercuric thiocyanate except when included in Schedule 6
Mercury, organic compounds of, except:
(a) for therapeutic use; or
(b) when included in Schedule 2, 6 or 7
Nux vomica
Phosphorus yellow (excluding its salts and derivatives) except in preparations containing 0.5% or less of free phosphorus
Savin, oil of
Stramonium except:
(i) in preparations for smoking or burning; or
(ii) when included in Schedule 2
Tansy, oil of
Veratrum, except for therapeutic use

SCHEDULE 2

Substances which are for therapeutic use and which require supervision of their distribution, such that their retail sale should be restricted to pharmacies and, where there is no pharmacy service available, general dealers in medicinal poisons

Acetic acid (excluding its salts and its derivatives) for therapeutic use in preparations containing more than 80% of acetic acid

Acetyldihydrocodeine when compounded with one or more other medicaments, in preparations containing 1% or less of acetyldihydrocodeine

Ammoniated mercury

Antazoline in preparations labelled and packed as eye drops or as nasal preparations for topical use

Aspirin and its preparations and derivatives except:

(a) tablets or capsules each containing 325 milligrams or less of aspirin as the only therapeutically active constituent when:

(i) the pack is labelled with the warning statement:
WARNING - THIS MEDICATION MAY BE DANGEROUS WHEN USED IN LARGE AMOUNTS OR FOR A LONG PERIOD; or
CAUTION - THIS PREPARATION IS FOR THE RELIEF OF MINOR AND TEMPORARY AILMENTS AND SHOULD BE USED STRICTLY AS DIRECTED. PROLONGED USE WITHOUT MEDICAL SUPERVISION COULD BE HARMFUL; and

(ii) packed in blister or strip packaging or in containers with a child-resistant closure; and

(iii) in a primary pack containing not more than 25 such tablets or capsules; or

(b) in individually wrapped powders each containing 650 milligrams or less of aspirin as the only therapeutically active constituent when:

(i) the pack is labelled with the warning statement:
WARNING - THIS MEDICATION MAY BE DANGEROUS WHEN USED IN LARGE AMOUNTS OR FOR A LONG PERIOD; or
CAUTION - THIS PREPARATION IS FOR THE RELIEF OF MINOR AND TEMPORARY AILMENTS AND SHOULD BE USED STRICTLY AS DIRECTED. PROLONGED USE WITHOUT MEDICAL SUPERVISION COULD BE HARMFUL; and

(ii) in a primary pack containing not more than 12 such powders or sachets of granules; or

(c) when included in Schedule 4.

Atropine, except atropine methonitrate, in preparations containing 0.25% or less of atropine and atropine sulphate, 0.6 mg tablets in packs of 6, when labelled for treatment of organophosphorus poisoning

Bamipine in preparations labelled and packed as eye drops or as nasal preparations for topical use

Belladonna herb in preparations containing 0.25% or less of the alkaloids of belladonna, calculated as hyoscyamine

Benzamine when included in:

(a) lozenges, pastilles, tablets and capsules containing 30 mg or less of benzamine in each;

(b) suppositories or bougies containing 200 mg or less of benzamine in each; or

(c) preparations for external use, other than eyedrops, containing 10% or less of benzamine

Benzocaine when included in:

(a) lozenges, pastilles, tablets and capsules containing 30 mg or less of benzocaine in each;

(b) suppositories or bougies containing 200 mg or less of benzocaine in each; or

(c) preparations for external use, other than eyedrops, containing 10% or less of benzocaine

Benzoyl peroxide in preparations for external human therapeutic use containing 5% or less benzoyl peroxide

Bromodiphenhydramine in preparations labelled and packed as eye drops or as nasal preparations for topical use

Bromhexine

Brompheniramine in preparations labelled and packed as eyedrops or as nasal preparations for topical use

Buclizine:

(a) in preparations labelled and packed for the treatment of motion sickness in packs of 10 doses or less; or

(b) in preparations labelled and packed as eye drops or as nasal preparations for topical case

Bufexamac in preparations containing 5% or less of bufexamac for external human therapeutic use, and in suppositories

Butylaminobenzoate when included in:

(a) lozenges, pastilles, tablets and capsules containing 30 mg or less of butylaminobenzoate in each;

(b) suppositories or bougies containing 200 mg or less of butylaminobenzoate in each; or

(c) preparations for external use, other than eyedrops, containing 10% or less of butylaminobenzoate

Cantharidin in preparations containing 0.01% or less of cantharidin

Carbaryl in preparations for external human therapeutic use containing 2% or less of carbaryl

Carbenoxolone for topical oral use

Carbetapentane citrate except in preparations containing 0.5% or less of carbetapentane

Carbinoxamine in preparations labelled and packed as eye drops or as nasal preparations for topical use

Chloroform (excluding its derivatives) except:
- (a) in preparations containing 10% or less of chloroform where the chloroform content is declared on the label; or
- (b) when included in Schedule 4

Chloropyrilene in preparations labelled and packed as eye drops or as nasal preparations for topical use
Chlorpheniramine in preparations labelled and packed as eye drops or as nasal preparations for topical use
Chlorphenoxamine in preparations labelled and packed as eye drops or as nasal preparations for topical use
Cinnamedrine:
Cinnarizine
- (a) in preparations labelled and packed as eye drops or as nasal preparations for topical use;
- (b) in solid dose preparations labelled and packed for the treatment of motion sickness, in packs of 10 doses or less

Clemastine in preparations labelled and packed as eye drops, or as nasal preparations for topical use
Clemizole in preparations labelled and packed as eye drops, or as nasal preparations for topical use
Clioquinol and other halogenated derivatives of 8-Hydroxyquinoline for external human use
Codeine:
- (a) when compounded in tablets or capsules with either aspirin or paracetamol or salicylamide or either one of their derivatives, and containing not more than 10 mg of codeine per tablet or capsule when:
  - (i) packed in blister or strip packaging or in containers with a child resistant closure; and
  - (ii) in a primary pack containing not more than 25 such tablets or capsules; or
- (b) compounded with one or more other medicaments, in divided preparations containing not more than 10 mg codeine per dosage unit; or
- (c) compounded with one or more other medicaments in undivided preparations with a concentration of not more than 0.5% of codeine

Cyanides - see hydrocyanic acid
Cycliramine in preparations labelled and packed as eye drops, or as nasal preparations for topical use
Cyproheptadine in preparations labelled and packed as eye drops or as nasal preparations for topical use
DDT in preparations for human therapeutic use
Deptropine in preparations labelled and packed as eye drops or as nasal preparations for topical use
Dexbrompheniramine in preparations labelled and packed as eye drops or as nasal preparations for topical use
Dexchlorpheniramine in preparations labelled and packed as eye drops or as nasal preparations for topical use
Dextromethorphan in preparations containing 1% or less of dextromethorphan when compounded with one or more other medicaments in such a way that the dextromethorphan contained therein cannot readily be extracted

Dextrorphan in preparations containing 1% or less of dextrorphan
Dicyclomine in preparations containing 0.1% or less of dicyclomine
Dihydrocodeine when compounded with one or more other medicaments, in preparations containing 1% or less or dihydrocodeine
Dimenhydrinate:
- (a) in preparations labelled and packed for the treatment of motion sickness in packs of 10 doses or less; or
- (b) in preparations labelled and packed as eye drops, or as nasal preparations for topical use

Dimethindene in preparations labelled and packed as eye drops or as nasal preparations for topical use
Dimethisoquin in preparations for topical use
Dimethothiazine in preparations labelled and packed as eye drops or as nasal preparations for topical use
Diphemanil methylsuphate in preparations for topical use.
Diphenhydramine:
- (a) in preparations labelled and packed for the treatment of motion sickness in packs of 10 doses or less; or
- (b) in preparations labelled and packed as eye drops or as nasal preparations for topical use

Diphenylpyraline in preparations labelled and packed as eye drops or as nasal preparations for topical use
Doxylamine in preparations labelled and packed as eye drops or as nasal preparations for topical use
Embramine in preparations labelled and packed as eye drops, or as nasal preparations for topical use
Ephedrine and pseudoephedrine except:
- (a) preparations containing 10 mg or less per dosage unit of ephedrine or pseudoephedrine; or
- (b) preparations for external use containing 1% or less of ephedrine or pseudoephedrine

Erythrityl tetranitrate and other nitric esters of polyhydric alcohols
Etafedrine
Ether (excluding its derivatives) except:
- (a) in preparations containing 10% or less of ether; or
- (b) when included in Schedule 4, 5 or 6

Ethoheptazine in preparations containing 1% or less of ethoheptazine
Ethylmorphine when compounded with one or more other medicaments, in preparations containing 1% or less of ethylmorphine
Ferrous sulphate and other iron preparations for human internal use, except in preparations containing 5% or less of iron
Fluorides in -
- (a) sodium fluoride in preparations for human ingestion containing 2.2 mg or less of sodium fluoride per dosage unit; or

(b) other metallic fluoride substances including ammonium fluoride when intended for therapeutic purposes except:
(i) in dentrifices containing 1000 mg/kg or less of fluoride ion; or
(ii) in substances containing 15 mg/kg or less of fluoride ion

Gelsemium

Glyceryl trinitrate except when included in Schedule 4

Guaiphenesin:
(a) in liquid preparations containing 2% or less or guaiphenesin (i.e. 200 mg/10 ml); or
(b) in solid dose preparations containing 120 mg or less of guaiphenesin in each dosage unit

Halopyramine in preparations labelled and packed as eye drops or as nasal preparations for topical use

Hexachlorophane in preparations for skin cleansing purposes containing 3% or less of hexachlorophane except:
(a) in preparations for use on infants; or
(b) in preparations for the treatment of animals

Histapyrrodine in preparations labelled and packed as eye drops or as nasal preparations for topical use

Homatropine in preparations containing 0.25% or less of homatropine

Human chorionic gonadotrophin in pregnancy test kits

Hydrocyanic acid in preparations containing the equivalent of 0.15% or less of hydrocyanic acid

8-Hydroxyquinoline and its derivatives, for human therapeutic use, except:
(a) non-halogenated derivatives, containing 1% or less for external use; or
(b) when included in Schedule 4

Hyoscine in preparations containing 0.25% or less of hyoscine, except hyoscine butylbromide

Hyoscyamine in preparations containing 0.25% or less hyoscyamine

Hyoscyamus in preparations containing 0.25% or less of the alkaloids of hyoscyamus calculated as hyoscyamine

Iodine (excluding its salts and derivatives) except:
(a) when included in Schedule 6;
(b) in iodophors in preparations containing 1.5% or less of available iodine; or
(c) in solid or semi-solid preparations containing 2.5% or less of available iodine

Isopropamide in preparations containing 2% or less of isopropamide for cutaneous use

Isosorbide dinitrate

Lead salts and compounds of lead when prepared for medical or cosmetic use, except in preparations for hair dressing containing 1% or less of lead

Lignocaine when included in:
(a) lozenges, pastilles, tablets and capsules containing 30 mg or less of lignocaine in each;
(b) suppositories or bougies containing 200 mg or less of lignocaine in each; or
(c) preparations for external use, other than eye drops, containing 10% or less of lignocaine

Lindane in preparations for external human therapeutic use containing 2% or less of lindane
Lobelia in preparations containing 0.5% or less of the alkaloids of lobelia, except preparations for smoking or burning
Maldison in preparations for external human therapeutic use containing 2% or less of maldison
Mebendazole for human therapeutic use
Mebhydrolin in preparations labelled and packed as eye drops or as nasal preparations for topical use
Mepyramine in preparations labelled and packed as eye drops or as nasal preparations for topical use
Mercuric chloride in preparations containing 0.5% or less of mercuric chloride, except:
(a) in batteries; or
(b) when included in Schedule 7
Mercuric iodide in preparations containing 2% or less of mercuric iodide, except when included in Schedule 6
Mercuric nitrate in preparations containing the equivalent of 3% or less of mercury (Hg) in such form
Mercuric oxide and all oxides of mercury
Mercuric-potassium iodide in preparations containing the equivalent of 2% or less of mercuric iodide, in such form
Mercury (metallic) (excluding its salts and derivatives) except in scientific instruments
Mercury, organic compounds of, in preparations containing the equivalent of 0.5% or less of mercury (Hg) except:
(a) when included in Schedule 6 or 7; or
(b) as a preservative in substances containing 0.01% or less of mercury
Methdilazine in preparations labelled and packed as eye drops or as nasal preparations for topical use
Methoxamine except:
(a) preparations containing 0.5% or less of methoxamine; or
(b) preparations for external use containing 1% or less of methoxamine
Methoxyphenamine
Methylephedrine
Naphazoline
Niclosamide for human therapeutic use
Nicocodine when compounded with one or more other medicaments, in preparations containing 1% or less of nicocodine
Nicodicodine when compounded with one or more other medicaments, in preparations containing 1% or less of nicodicodine
Norcodeine when compounded with one or more other medicaments, in preparations containing 1% or less of norcodeine
Noscapine
Octyl nitrite
Oxethazaine in preparations for internal use only
Oxolamine
Oxymetazoline
Papaverine

Paracetamol and its preparations and derivatives except:
- (a) tablets or capsules each containing 500 milligrams or less of paracetamol as the only therapeutically active constituent when:
  - (i) the pack is labelled with the warning statement:
    WARNING - THIS MEDICATION MAY BE DANGEROUS WHEN USED IN LARGE AMOUNTS OR FOR A LONG PERIOD; or
    CAUTION - THIS PREPARATION IS FOR THE RELIEF OF MINOR AND TEMPORARY AILMENTS AND SHOULD BE USED STRICTLY AS DIRECTED. PROLONGED USE WITHOUT MEDICAL SUPERVISION COULD BE HARMFUL;
  - (ii) packed in blister or strip packaging or in containers with a child resistant closure; and
  - (iii) in a primary pack containing not more than 25 such tablets or capsules;
- (b) in individually wrapped powders each containing 1000 milligrams or less of paracetamol as the only therapeutically active constituent when:
  - (i) the pack is labelled with the warning statement:
    WARNING - THIS MEDICATION MAY BE DANGEROUS WHEN USED IN LARGE AMOUNTS OR FOR A LONG PERIOD; or
    CAUTION - THIS PREPARATION IS FOR THE RELIEF OF MINOR AND TEMPORARY AILMENTS AND SHOULD BE USED STRICTLY AS DIRECTED. PROLONGED USE WITHOUT MEDICAL SUPERVISION COULD BE HARMFUL; and
  - (ii) in a primary pack containing not more than 12 such powders or sachets of granules; or
- (c) when included in Schedule 4

Phedrazine

Phenamazoline

Phenazone for external use

Phenindamine in preparations labelled and packed as eye drops or as nasal preparations for topical use

Pheniramine
- (a) in preparations labelled and packed for the treatment of motion sickness in packs of 10 doses or less; or
- (b) in preparations labelled and packed as eye drops or as nasal preparations for topical use

Phenol and any homologue of phenol boiling below 220°C, creosote, for therapeutic use except in preparations containing 3% or less by weight of such substances or homologues

Phenylene diamines, toluene and all other alkylated benzene diamine derivatives except when included in Schedule 6

Phenylephrine except:
- (a) preparations containing 0.5% or less of phenylephrine; or

(b) preparations for external use containing 1% or less of phenylephrine

Phenyltoloxamine in preparations labelled and packed as eye drops or as nasal preparations for topical use

Pholcodine when compounded with one or more other medicaments, in preparations containing 1% or less of pholcodine

Potassium chlorate except in preparations containing 10% or less of potassium chlorate

Procyclidine in preparations containing 5% or less of procyclidine for cutaneous use

Promethazine

(a) in preparations labelled and packed for the treatment of motion sickness in packs of 10 doses or less; or

(b) in preparations labelled and packed as eye drops or as nasal preparations for topical use

Propantheline in preparations for topical use

Propoxur in preparations for external human therapeutic use containing 0.2% or less of propoxur

Propylhexedrine in appliances for inhalation in which the substance is absorbed upon an inert solid material

Propyphenazone

Pyrantel for human therapeutic use

Pyrrobutamine in preparations labelled and packed as eye drops or as nasal preparations for topical use

Salicylamide and its preparations and derivatives except:

(a) tablets or capsules each containing 500 milligrams or less of salicylamide as the only therapeutically active constituent when:

(i) the pack is labelled with the warning statement:
WARNING - THIS MEDICATION MAY BE DANGEROUS WHEN USED IN LARGE AMOUNTS OR FOR A LONG PERIOD; or
CAUTION - THIS PREPARATION IS FOR THE RELIEF OF MINOR AND TEMPORARY AILMENTS AND SHOULD BE USED STRICTLY AS DIRECTED. PROLONGED USE WITHOUT MEDICAL SUPERVISION COULD BE HARMFUL;

(ii) packed in blister or strip packaging or in containers with a child resistant closure; and

(iii) in a primary pack containing not more than 25 such tablets or capsules;

(b) in individually wrapped powders each containing 1000 milligrams or less of salicylamide as the only therapeutically active constituent when:

(i) the pack is labelled with the warning statement:
WARNING - THIS MEDICATION MAY BE DANGEROUS WHEN USED IN LARGE AMOUNTS OR FOR A LONG PERIOD; or
CAUTION - THIS PREPARATION IS FOR THE RELIEF OF MINOR AND TEMPORARY AILMENTS AND SHOULD BE USED STRICTLY AS DIRECTED.

PROLONGED USE WITHOUT MEDICAL SUPERVISION COULD BE HARMFUL; and

(ii) in a primary pack containing not more than 12 such powders or sachets of granules; or

(c) when included in Schedule 4

Silver nitrate
Sodium nitrite for therapeutic use
Staphisagria except in preparations containing 0.2% or less of staphisagria
Stramonium in preparations containing 0.25% or less of the alkaloids calculated as hyoscyamine, except preparations for smoking or burning
Tetrahydrozoline
Thenalidine in preparations labelled and packed as eye drops
Thenyldiamine in preparations labelled and packed as eye drops or as nasal preparations for topical use
Tolpropamine in preparations labelled and packed as eye drops or as nasal preparations for topical use
Tramazoline
Trimeprazine in preparations labelled and packed as eye drops or as nasal preparations for topical use
Trimethobenzamide in preparations labelled and packed as eye drops or as nasal preparations for topical use
Trimizoline
Tripelennamine in preparations labelled and packed as eye drops or as nasal preparations for topical use
Triprolidine in preparations labelled and packed as eye drops or as nasal preparations for topical use
Tymazoline
Xylometazoline
Zinc pyrithione except in preparations containing 2% or less of zinc pyrithione

---

SCHEDULE 3

Substances which are for therapeutic use and which are of a sufficiently dangerous nature to warrant their distribution to be restricted to pharmacists and medical practitioners, dentists and veterinary surgeons

Adrenaline in preparations containing 1% or less of adrenaline except in preparations containing 0.01% or less of adrenaline

Amyl nitrite

Antazoline:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the product bears a label warning that the product is not suitable for children under 8 years of age

Bamipine:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the product bears a label warning that the product is not suitable for children under 8 years of age

Benzoyl peroxide in preparations containing 10% or less benzoyl peroxide for external human therapeutic use, except when included in Schedule 2

Bromodiphenhydramine:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the product bears a label warning that the product is not suitable for children under 8 years of age

Brompheniramine:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the

product bears a label warning that the product is not suitable for children under 8 years of age

Buclizine:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the product bears a label warning that the product is not suitable for children under 8 years of age

Butyl nitrite

Carbinoxamine:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the product bears a label warning that the product is not suitable for children under 8 years of age

Chloral hydrate in preparations containing 5% or less of chloral hydrate, when packed in containers of 100 ml or less

Chloropyrilene:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the product bears a label warning that the product is not suitable for children under 8 years of age

Chlorpheniramine:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the product bears a label warning that the product is not suitable for children under 8 years of age

Chlorphenoxamine:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the product bears a label warning that the product is not suitable for children under 8 years of age

Cholestyramine for human therapeutic use

Cinnarizine:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the product bears a label warning that the product is not suitable for children under 8 years of age

Clemastine:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the product bears a label warning that the product is not suitable for children under 8 years of age

Clemizole:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the product bears a label warning that the product is not suitable for children under 8 years of age

Codeine when compounded in tablets or capsules with either aspirin or paracetamol or salicylamide or either of their derivatives, and containing not more than 10 mg of codeine per tablet or capsule, except when included in Schedule 2

Colestipol for human therapeutic use

Cycliramine:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the

product bears a label warning that the product is not suitable for children under 8 years of age

Cyproheptadine:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the product bears a label warning that the product is not suitable for children under 8 years of age

Deptropine:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the product bears a label warning that the product is not suitable for children under 8 years of age

Dexbrompheniramine:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the product bears a label warning that the product is not suitable for children under 8 years of age

Dexchlorpheniramine:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the product bears a label warning that the product is not suitable for children under 8 years of age

Dimenhydrinate:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the

product bears a label warning that the product is not suitable for children under 8 years of age

Dimethindene:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the product bears a label warning that the product is not suitable for children under 8 years of age

Dimethothiazine:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the product bears a label warning that the product is not suitable for children under 8 years of age

Diphenhydramine:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the product bears a label warning that the product is not suitable for children under 8 years of age

Diphenylpyraline:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the product bears a label warning that the product is not suitable for children under 8 years of age

Dithranol for human therapeutic use

Doxylamine:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the

product bears a label warning that the product is not suitable for children under 8 years of age

Embramine:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the product bears a label warning that the product is not suitable for children under 8 years of age

Fenoterol in metered aerosols delivering 200 micrograms or less of fenoterol per metered dose

Flavoxate

Folic acid for human therapeutic use except in preparations containing 500 micrograms or less of folic acid per recommended daily dose

Folinic acid for human therapeutic use except in preparations containing 500 micrograms or less of folinic acid per recommended daily dose

Halopyramine:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the product bears a label warning that the product is not suitable for children under 8 years of age

Histapyrrodine:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the product bears a label warning that the product is not suitable for children under 8 years of age

Idoxuridine in preparations containing 0.5% or less idoxuridine for cutaneous use

Insulin and preparations containing the specific hypoglycaemic principle of the pancreas

Isoprenaline:

(a) in solutions for inhalation containing 1% or less of isoprenaline; or

(b) in metered dose aerosols delivering 100 micrograms or less of isoprenaline per metered dose

Mebhydrolin:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the product bears a label warning that the product is not suitable for children under 8 years of age

Mefenamic acid in packs of 30 capsules or less when labelled for treatment of spasmodic dysmenorrhea

Mepyramine:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the product bears a label warning that the product is not suitable for children under 8 years of age

Methdilazine:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the product bears a label warning that the product is not suitable for children under 8 years of age

Nitrofurazone, in preparations for cutaneous use containing 0.2% or less of nitrofurazone

Orciprenaline in metered aerosols delivering 750 micrograms or less of orciprenaline per metered dose

Phenindamine:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the product bears a label warning that the product is not suitable for children under 8 years of age

Pheniramine:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the product bears a label warning that the product

is not suitable for children under 8 years of age

Phenylpropanolamine in preparations containing 50 mg or less per dose of phenylpropanolamine for relief of coughs or colds

Phenyltoloxamine:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the product bears a label warning that the product is not suitable for children under 8 years of age

Promethazine:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the product bears a label warning that the product is not suitable for children under 8 years of age

Pyrrobutamine:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the product bears a label warning that the product is not suitable for children under 8 years of age

Quinine for human therapeutic use

Salbutamol in metered aerosols delivering 100 micrograms or less of salbutamol per metered dose

Santonin

Sodium cromoglycate in nasal preparations, topically applied

Terbutaline in metered aerosols delivering 250 micrograms or less of terbutaline per metered dose

Thenalidine:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the product bears a label warning that the product is not suitable for children under 8 years of age

Thenyldiamine:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the product bears a label warning that the product is not suitable for children under 8 years of age

Theophylline and derivatives therefrom in oral liquid preparations

Tolpropamine:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the product bears a label warning that the product is not suitable for children under 8 years of age

Tretinoin for external human therapeutic use

Trimeprazine:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the product bears a label warning that the product is not suitable for children under 8 years of age

Trimethobenzamide:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the product bears a label warning that the product is not suitable for children under 8 years of age

Tripelennamine:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the

product bears a label warning that the product is not suitable for children under 8 years of age

Triprolidine:

(a) in oral solid preparations except when included in Schedule 2; or

(b) in oral liquid preparations when compounded with one or more of the following medicaments: an antitussive, an expectorant or a sympathomimetic amine, when packed, labelled and sold for the relief of coughs and colds, provided that the product bears a label warning that the product is not suitable for children under 8 years of age

---

SCHEDULE 4

Substances or preparations, the supply of which, in the public interest, should be restricted to medical, dental or veterinary prescription, together with potentially harmful substances or preparations pending the evaluation of their toxic or deleterious nature

Acetanilide and alkyl acetanilides, for human therapeutic use
Acetazolamide
Acetohexamide
Acetylcholine and other choline esters
Acetylcysteine
Acetyldihydrocodeine when compounded with one or more other medicaments:
- (a) in divided preparations containing not more than 100 mg of acetyldihydrocodeine per dosage unit; or
- (b) in undivided preparations with a concentration of not more than 2.5% of acetyldihydrocodeine;

except when included in Schedule 2
Acetylmethyldimethyloximidophenylhydrazine
Adiphenine
Adrenaline, natural or synthetic, except in preparations containing 1% or less of adrenaline
Alcuronium
Alphadolone
Alpha-receptor blocking agents including phentolamine and phenoxybenzamine
Alphaxalone
Alprazolam
Amantadine
Ambenonium
Ambucetamide
Ambutonium
Amethocaine
Amikacin
Amiloride
Aminometradine
Aminophenazone and derivatives therefrom for animal use
Aminopterin
Aminorex
Amiphenazole
Amisometradine
Amitriptyline and other compounds not elsewhere specified in these schedules structurally derived therefrom by substitution in the side chain
Amodiaquine
Amoxycillin
Amphomycin
Amphotericin
Ampicillin
Amylocaine
Anabolic steroidal agents

Anaesthetics, local, being synthetic cocaine substitutes, except when included in Schedule 2
Angiotensin amide
Antazoline except when included in Schedule 2 or 3
Antibiotics not elsewhere specified except:
(a) Avoparcin when intended for use as an animal feed additive; or
(b) Nisin
Antifolic acid substances not elsewhere specified in these schedules
Antihistamines not elsewhere specified in these schedules except when included in Schedule 2 or 3
Antimalarial substances not elsewhere specified in these schedules
Antimony, organic compounds of, for therapeutic use
Antitubercular substances not elsewhere in these schedules including isoniazid and its derivatives, paraaminosalicylic acid and thiacetazone
Apomorphine
Aprotinin
Aspirin when combined with caffeine, paracetamol or salicylamide or any derivative of these substances
Atenolol
Atropine methonitrate
Azaperone
Azapetine
Azatadine
Azlocillin
Bacitracin except:
(a) when included in Schedule 6;
(b) in animal feedstuffs for growth promotion in concentrations of 50 mg/kg or less of the total active antibiotic principle; or
(c) in milk replacers for calves and starter rations for pigs in concentrations of 100 mg/kg or less of the total active antibiotic principle
Baclofen
Bamipine except when included in Schedule 2 or 3
Barbituric acid and its derivatives
Beclamide
Bemegride
Benactyzine and other substances structurally derived from diphenylmethane with ataractic properties when used for therapeutic purposes
Benserazide
Benzamine, except when included in Schedule 2
Benzhexol
Benzilonium
Benzocaine, except when included in Schedule 2
Benzoyl peroxide in preparations for external human therapeutic use, except when included in Schedule 2 or 3
Benzphetamine and other substances structurally derived from beta-aminopropylbenzene or beta-aminoisoproply-benzene by substitution in the side-chain or by ring-closure therein (or by both such substitution and such closure) except:

(a) when in Schedule 2 or 8; or
(b) ephedrine, pseudoephedrine and phenylephrine in preparations exempted from Schedule 2

Benztropine
Benzydamine
Benzylpenicillin (including procaine pencillin) except when included in Schedule 6
Betahistine
Beta-receptor blocking agents including alprenolol and propranolol
Bethanidine
Biperiden
Bismuth, compounds of, for human therapeutic or cosmetic use, except bismuth citrate when incorporated in hair colourant preparations in concentrations of 0.5% w/w or less
Bleomycin
Boron compounds for human therapeutic or cosmetic use except:
(a) in preparations for external use containing 1% or less of boron; or
(b) in unit dose preparations for periodontal disease containing 100 mg or less of boron

Bretylium
Bromides, inorganic, for therapeutic use
Bromocriptine
Bromodiphenhydramine except when included in Schedule 2 or 3
Bromoform for therapeutic use
Brompheniramine except when included in Schedule 2 or 3
Bromvaletone
Buclizine except when included in Schedule 2 or 3
Bufexamac except when included in Schedule 2
Bumetanide
Buprenorphine
Busulphan
Butacaine
Butylaminobenzoate except when included in Schedule 2
Butylchloral hydrate
Calcitonin
Calcitriol
Calcium carbimide for therapeutic use
Camphotamide
Candicidin
Cantharidin except when included in Schedule 2
Capreomycin
Captodiame
Captopril
Capuride
Caramiphen
Carbachol
Carbamazepine
Carbaryl for human therapeutic use except when included in Schedule 2
Carbazochrome
Carbenicillin
Carbenoxolone except when included in Schedule 2

Carbidopa
Carbimazole
Carbinoxamine except when included in Schedule 2 or 3
Carbocromen
Carbromal
Cardiac glycosides not elsewhere specified in these schedules
Carindacillin
Cefaclor
Cefotaxime
Cefoxitin
Cephacetrile
Cephalexin
Cephaloridine
Cephalothin
Cephamandole
Cephazolin
Cephradine
Cephapirin
Chenodeoxycholic acid
Chloral formamide
Chloral hydrate except when included in Schedule 3
Chloramphenicol for human and animal use
Chlorazanil
Chlorbutol in preparations for human oral use, except in preparations containing 0.5% or less of chlorbutol as a preservative
Chlorcyclizine
Chlordiazepoxide and other substances structurally derived from benzodiazepine with ataractic properties when used for therapeutic purposes
Chlormerodrin
Chlormethiazole
Chlormezanone
Chloroform when specifically prepared and packed as a therapeutic agent for the induction of inhalation anaesthesia
1-(4-Chlorophenoxy)-1-Imidazol-1-YL-3, -3 Dimethyl-2-Butanone for human use
Chloropyrilene except when included in Schedule 2 or 3
Chloroquine
Chlortetracycline except when included in Schedule 6
Chlorothiazide and other substances structurally derived from benzothiadiazine for therapeutic use
Chlorpheniramine except when included in Schedule 2 or 3
Chlorphentermine
Chlorpromazine and other substances structurally derived from phenothiazine with ataractic properties when used for therapeutic purposes
Chlorpropamide
Chlorprothixene
Chlorthalidone
Chlorzoxazone
Cimetidine
Cinchocaine
Cinnarizine except when included in Schedule 2 or 3
Cinoxacin

Cistplatin
Clemastine except when included in Schedule 2 or 3
Clemizole except when included in Schedule 2 or 3
Clidinium
Clindamycin
Clobetasone-17-Butyrate
Clofenamide
Clofibrate
Clomipramine
Clomocycline
Clonazepam
Clonidine
Clopamide
Cloprostenol for treatment of animals
Clorazepate
Clorexolone
Clotrimazole
Cloxacillin
Clozapine
Codeine when compounded with one or more other medicaments:
(a) in divided preparations containing not more than 30 mg of codeine per dosage unit; or
(b) in undivided preparations with a concentration of not more than 1% of codeine,
except when included in Schedule 2
Colaspase
Colchicine
Colistin
Cortisone and steroid suprarenal cortical hormones, either natural or synthetic
Coumarin derivatives and phenylindanedione derivatives for therapeutic use
Curare, tubocurarine, d-tubocurarine, d-tubocurarinedimethylether, and all synthetic quaternary ammonium compounds, and other compounds having curarising properties
Cyclandelate
Cycliramine except when included in Schedule 2 or 3
Cyclizine
Cyclopentolate
Cyclopropane when specifically prepared and packed as a therapeutic agent for the induction of inhalation anaesthesia
Cycloserine
Cycrimine
Cyproheptadine except when included in Schedule 2 or 3
Dacarbazine
Danazol
Dantrolene
Dapsone and all derivatives of 4,4-diaminodiphenylsulphone
Deanol
Demecarium bromide
Demeclocycline
Deptropine except when included in Schedule 2 or 3
Desipramine
Desmopressin (D.D.A.V.P.)

Dexbrompheniramine except when included in Schedule 2 or 3
Dexchlorpheniramine except when included in Schedule 2 or 3
Dextromethorphan except when included in Schedule 2
Dextrorphan except in preparations containing 1% or less of dextrorphan
Dibenzepin
Dichloralphenazone
Dichlorphenamide
Diclofenac
Dicyclomine except in preparations containing 0.1% or less of dicyclomine
Diethazine
Diethylcarbamazine for human therapeutic use
Diethylpropion
Difenoxin in preparations containing, per dosage unit, 0.5 mg or less of difenoxin and a quantity of atropine sulphate equivalent to at least 5% of the dose of difenoxin
Diflunisal
Digitalis and its glycosides
Dihydralazine
Dihydrocodeine when compounded with one or more other medicaments:
(a) in divided preparations containing not more than 100 mg of dihydrocodeine per dosage unit; or
(b) in undivided preparations with a concentration of not more than 2.5% of dihydrocodeine;
except when included in Schedule 2
Dihydrostreptomycin except when included in Schedule 6
Diisopropylamine dichloroacetate
Dimenhydrinate except when included in Schedule 2 or 3
Dimethindene except when included in Schedule 2 or 3
Dimethisoquin except when included in Schedule 2
Dimethothiazine except when included in Schedule 2 or 3
Dimethoxanate
Dimethyl sulphoxide for therapeutic use
Dinitrocresols for therapeutic use
Dinitronaphthols for thereapeutic use
Dinitrophenols for therapeutic use
Dinitrothymols for therapeutic use
Dinoprost for treatment of animals
Diperodon
Diphemanil methylsulphate except in preparations for topical use
Diphenhydramine except when included in Schedule 2 or 3
Diphenidol
Diphenoxylate in preparations containing, per dosage unit, 2.5 mg or less of diphenoxylate calculated as base, and a quantity of atropine sulphate equivalent to at least 1% of the dose of diphenoxylate
Diphenylpyraline except when included in Schedule 2 or 3
Dipivefrin
Dipyridamole
Disophenol

Disopyramide
Disulfiram except when used for industrial purposes
Dithiazanine except in preparations containing 2% or less of dithiazanine for the treatment of animals
Dobutamine
Dopramine
Dothiepin
Doxapram
Doxepin
Doxorubicin
Doxycycline (vibramycin)
Doxylamine except when included in Schedule 2 or 3
Droperidol
Drostanolone
Econazole except when included in Schedule 6
Embramine except when included in Schedule 2 or 3
Emetine except in preparations containing 0.2% or less of emetine
Enflurane when specifically prepared and packed as a therapeutic agent for the induction of inhalation anaesthesia
Epicillin
Ergot
Erythromycin except:
(a) when included in Schedule 6;
(b) in animal feedstuffs for growth promotion in concentrations of 50 mg/kg or less of the total active antibiotic principle; or
(c) in milk replacers for calves or starter rations for pigs in concentrations of 100 mg/kg or less of the total active antibiotic principle
Ethacrynic acid
Ethambutol
Ethamivan
Ethchlorvynol
Ether when specifically prepared and packed as a therapeutic agent for the induction of inhalation anaesthesia
Ethinamate
Ethoglucid
Ethoheptazine except in preparations containing 1% or less of ethoheptazine
Ethopropazine
Ethoxzolamide
Ethyl chloride when specifically prepared and packed as a therapeutic agent for the induction of inhalation anaesthesia
Ethylene when specifically prepared and packed as a therapeutic agent for the induction of inhalation anaesthesia
Ethylmorphine when compounded with one or more other medicaments -
(a) in divided preparations containing not more than 100 mg of ethylmorphine per dosage unit; or
(b) in undivided preparations with a concentration of not more than 2.5% of ethylmorphine;
except when included in Schedule 2
Ethyloestrenol

Etidocaine
Etidronate
Etoposide
Fencamfamin
Fenfluramine
Fenoprofen
Fenoterol except when included in Schedule 3
Fenpipramide
Fenpiprane
Fenprostalene for the treatment of animals
Flavophospholipol except:
(a) when included in Schedule 6; or
(b) in animal feedstuffs for growth promotion in concentrations of 50 mg/kg or less of the total active antibiotic principle
Flucloxacillin
Flucytosine
Flufenamic acid
Flunisolide
Flunitrazepam
Fluorouracil and other substances structurally derived from uracil with cytotoxic properties when used for therapeutic purposes
Fluoxymesterone
Fluprostanol for treatment of animals
Flurazepam
Fluroxene when specifically prepared and packed as a therapeutic agent for the induction of inhalation anaesthesia
Fluspirilene
Framycetin
Frusemide
Fusidic acid
Galanthamine
Gallamine
Gentamycin
Glibornuride
Gliclazide
Glucagon
Glutethimide
Glyceryl trintrate in preparations for injection
Glycopyrrolate
Glymidine
Gramicidin
Griseofulvin
Guanacline
Guanethidine
Halcinonide
Haloperidol and other substances structurally derived from butyrophenone with ataractic properties when used for therapeutic purposes
Halopyramine except when included in Schedule 2 or 3
Halothane when specifically prepared and packed as a therapeutic agent for the induction of inhalation anaesthesia
Heparin
Hetacillin

Hexachlorophane in preparations for use on infants and in all other preparations except when included in Schedule 2 or 6
Hexamethonium
Hexocyclium
Histapyrrodine except when included in Schedule 2 or 3
Hydralazine
Hydroquinone for human therapeutic use except in preparations containing 2% or less of hydroquinone
Hydroxychloroquine
1-Hydroxypyrido (3,2,a)-5-phenoxazone-3-carboxylic acid
Hydroxyurea
Hydroxyzine
Hygromycin except:
(a) when included in Schedule 6; or
(b) in preparations in concentrations of 50 mg/kg or less of hygromycin
Hyoscine butylbromide
Hypothalmic releasing factors when used for diagnostic purposes
Ibufenac
Ibuprofen
Idoxuridine except when included in Schedule 3
Imipramine
Indomethacin
Inositol nicotinate, for internal use
Ion-exchange resins, anionic and cationic, for internal use in humans
Ipratropium
Iron compounds, injectable preparations for human therapeutic use
Isoaminile
Isoetharine
Isometheptene
Isoprenaline except when included in Schedule 3
Isopropamide except when included in Schedule 2
Isoxuprine
Kanamycin
Ketamine
Ketoprofen
Khellin
Kitasamycin, except:
(a) when included in Schedule 6;
(b) in animal feedstuffs for growth promotion in concentrations of 100 mg/kg or less of the total active antibiotic principle
Labetalol
Laudexium methylsulphate
Lefetamine
Leptazol
Levamisole for human therapeutic use
Levodopa
Lidoflazine
Lignocaine except when included in Schedule 2
Lincomycin
Lithium salts for therapeutic use, except in preparations containing 0.01% or less of lithium

Loperamide
Lorazepam
Loxapine
Lymecycline
Mafenide
Maprotiline
Mazindol
Mebeverine
Mebhydrolin except when included in Schedule 2 or 3
Mecamylamine
Meclofenoxate
Meclozine
Medazepam
Mefenamic acid except when included in Schedule 3
Mefloquine
Mefruside
Mepacrine
Mepenzolate
Mephenesin and its derivatives except guaiphenesin when included in Schedule 2
Mephentermine
Mepivacaine
Meprobamate
Mepyramine except when included in Schedule 2 or 3
Mercaptopurine and other substances structurally derived therefrom with cytotoxic properties when used for therapeutic purposes
Mercurous chloride for therapeutic use
Mercury, organic compounds of, for therapeutic use, except preparations for topical use containing 0.5% or less of mercury
Metaraminol
Metformin
Methacycline
Methandienone
Methandriol
Methanthelinium
Methazolamide
Methdilazine except when included in Schedule 2 or 3
Methenolone
Methicillin
Methimazole
Methixene
Methocarbamol
Methotrexate
Methoxsalen
Methoxyflurane when specifically prepared and packed as a therapeutic agent for the induction of inhalation anaesthesia
Methlandrostanolone
Methyldopa
Methyl pentynol and other substituted alkynes for internal use
Methyprylone
Metoclopramide
Metolazone
Metoprolol

Metrizamide
Metronidazole including benzoylmetronidazole
Metyrapone
Mexiletine
Mezlocillin
Mianserin
Mibolerone
Miconazole
Minocycline
Minoxidil
Mithramycin
Mitobronitol
Mitomycin
Monensin except:
(a) in animal feedstuffs containing 120 mg/kg or less of monensin; or
(b) when included in Schedule 6
Monoamine oxidase inhibitors, including iproniazid, isocarboxazid, nialamide, phenelzine, pheniprazine and other preparations for which monoamine oxidase inhibition is claimed, except triparanol
Monobenzone for human therapeutic use except in preparations containing 2% or less of monobenzone
Moperone
Morphine antagonists including nalorphine, naloxone and levallorphan
Mustine and other substances structurally derived therefrom with cytotoxic properties, when used for therapeutic purposes
Nalidixic acid
Nandrolone
Naproxen
Natamycin
Neomycin except when included in Schedule 6
Neostigmine
Netilmicin
Nicocodine when compounded with one or more other medicaments:
(a) in divided preparations containing not more than 100 mg of nicocodine per dosage unit; or
(b) in undivided preparations with a concentration of not more than 2.5% of nicocodine,
except when included in Schedule 2
Nicodicodine when compounded with one or more other medicaments:
(a) in divided preparations containing not more than 100 mg of nicodicodine per dosage unit; or
(b) in undivided preparations with a concentration of not more than 2.5% of nicodicodine
except when included in Schedule 2
Nicotine, in chewing tablets containing 4 mg or less of nicotine per tablet, for use as an aid in withdrawal from tobacco smoking
Nicotinic acid, where the recommended daily dose exceeds 250 mg
Nicotinyl alcohol for internal use
Nifedipine

Nifenazone
Nikethamide
Niridazole
Nitrazepam
Nitrous oxide when specifically prepared and packed as a therapeutic agent for the induction of inhalation anaesthesia
Nitrofuran and its derivates for human therapeutic use
Nomifensine
Noradrenaline (excluding its derivatives)
Norcodeine when compounded with one or more other medicaments:
(a) in divided preparations containing not more than 100 mg of norcodeine per dosage unit; or
(b) in undivided preparations with a concentration of not more than 2.5% of norcodeine,
except when included in Schedule 2
Norethandrolone
Nortriptyline
Novobiocin except when included in Schedule 6
Octamylamine
Octatropine
Oleandomycin except:
(a) when included in Schedule 6; or
(b) in animal feedstuffs for growth promotion in concentrations of 50 mg/kg or less of the total active antibiotic principle
Opipramol
Orciprenaline except when included in Schedule 3
Organophosphorus compounds with anticholinesterase activity for human therapeutic use, except when included in Schedule 2
Ornidazole
Ornipressin
Orphenadrine
Orthocaine
Orthopterin
Oxacillin
Oxandrolone
Oxazepam
Oxprenolol
Oxybuprocaine
Oxymesterone
Oxymetholone
Oxyphenbutazone
Oxyphencyclimine
Oxyphenonium
Oxytetracycline except when included in Schedule 6
Pamaquine
Pancuronium
Paracetamol when combined with aspirin, caffeine or salicylamide or any derivative of these substances
Paraldehyde
Paromomycin
Pemoline
Pempidine
D-Penicillamine

Pentamethonium
Penthienate
Pentolinium
Perhexilene
Phenacemide and other substances structurally derived from acetylurea with anticonvulsant properties when used for therapeutic purposes
Phenacetin
Phenazone for internal use
Phenazopyridine
Phenethicillin except when included in Schedule 6
Phenformin
Phenglutarimide
Phenindamine except when included in Schedule 2 or 3
Pheniramine except when included in Schedule 2 or 3
Phenoxybenzamine
Phenoxymethylpenicillin except when included in Schedule 6
Phensuximide and other substances structurally derived from succinamide with anticonvulsant properties when used for therapeutic purposes
Phentermine
Phenthimentonium
Phenyapin
Phenylbutazone
Phenylpropanolamine except when included in Schedule 3
Phenyltoloxamine except when included in Schedule 2 or 3
Phenytoin and other substances structurally derived from hydantoin with anticonvulsant properties when used for therapeutic purposes
Pholcodine when compounded with one or more other medicaments:
(a) in divided preparations containing not more than 100 mg of pholcodine per dosage unit; or
(b) in undivided preparations with a concentration of not more than 2.5% of pholcodine;
except when included in Schedule 2
Physostigmine
Picrotoxin
Pilocarpine except in preparations containing 0.025% or less of pilocarpine
Pimozide
Pindolol
Pipenzolate
Piperidolate
Pipobroman
Pipradrol
Pituitary, its extracts, its active principles or their synthetic substitutes except when included in Schedule 7
Pizotifen
Polymethylene bistrimethyl ammonium compounds
Polymyxin
Potassium perchlorate for therapeutic use
Prazepam
Pregnenolone acetate except in preparations for topical use
Prenylamine
Prilocaine

Primaquine
Primidone
Prioxican
Probenecid
Procainamide
Procaine
Procarbazine
Prochlorperazine
Procyclidine except when included in Schedule 2
Proguanil
Prolintane
Promethazine except when included in Schedule 2 or 3
Propanidid
Propantheline except in preparations for topical use
Propylhexedrine except when included in Schedule 2
Proquazone
Prostainol, for treatment of animals
Prothionamide
Protriphyline
Proxymetacaine
Pyridostigmine
Pyrimethamine
Pyrrobutamine except when included in Schedule 2 or 3
Quinethazone
Quinidine
Ranitidine
Rauwolfia serpentina
Rifampicin
Ritodrine
Roliteracycline
Salbutamol except when included in Schedule 3
Salinomycin except:
- (a) in animal feedstuffs containing 60 mg/kg or less of the total active principle; or
- (b) when included in Schedule 6

Salicylamide when combined with aspirin, caffeine or paracetamol or any derivative of these substances
Selenium, compounds of, except:
- (a) when included in Schedule 5 or 6;
- (b) when included in animal feedstuffs containing 0.1 g/tonne or less of selenium in total feed; or
- (c) in compressed pellets for control of selenium responsive conditions in sheep

Sex hormones, natural or synthetic, their substitutes in all preparations, including cosmetics, except:
- (a) their derivatives and their substitutes without sex hormonal activity; or
- (b) when specifically named in this or any other Schedule

Sisomycin
Sodium cromoglycate except when included in Schedule 3
Sodium fluoride, in preparations for human ingestion except when included in Schedule 2
Sodium nitroprusside, for human therapeutic use
Sodium valproate
Sontoquine

Sparteine
Spectinomycin
Spiramycin, except:
(a) when included in Schedule 6; or
(b) in animal feedstuffs for growth promotion in pigs or poultry in concentrations of 50 mg/kg or less of the total active antibiotic principle
Spironolactone
Stanolone
Stanozolol
Streptomycin except when included in Schedule 6
Strophanthus and its glycosides
Strychnine in preparations containing 1.5% or less of strychnine for the treatment of animals
Sulindac
Sulphanilamide, and its derivates except:
(a) when included in Schedule 6;
(b) sulphaquinoxaline when incorporated in baits for the destruction of vermin and in animal feedstuffs containing 200 mg/kg or less of sulphaquinoxaline;
(c) Oryzalin; or
(d) when specifically named in this or any other Schedule
Sulphatroxazole
Sulphinpyrazone
Sulphomyxin
Sulphonal and alkyl sulphonals
Sulthiame
Suxamethonium
Tacrine
Tamoxifen
Temazepam
Terbutaline except when included in Schedule 3
Teropterin
Tetrabenazine
Tetracycline except when included in Schedule 6
Thenalidine except when included in Schedule 2 or 3
Thenyldiamine except when included in Schedule 2 or 3
Theophylline and derivatives therefrom except when included in Schedule 3
Thiacetarsamioe, in preparations for the prevention of heart worm in dogs
Thiambutosine
Thiazosulphone
Thiotepa and other substances structurally derived therefrom with cytotoxic properties when used for therapeutic purposes
Thiothixene
Thiouracil and substances structurally derived therefrom with antithyroid properties when used for therapeutic purposes
Thiourea for therapeutic use
Thyroid and its extract, and its active principles
Tiamulin
Ticarcillin
Tiemonium

Tigloidine
Timolol
Tinidazole
Tipepidine
Tolazamide
Tolazoline for internal use
Tolbutamide
Tolpropamine except when included in Schedule 2 or 3
Tranexamic acid
Tretamine
Triamterene
Triaziquone
Triazolam
Trichloroethylene when specifically prepared and packed as a therapeutic agent for the induction of inhalation anaesthesia
Triclofos
Tricyclamol
Tridihexethyl
Trifluperidol
Trimeprazine except when included in Schedule 2 or 3
Trimetaphan
Trimethobenzamide except when included in Schedule 2 or 3
Trimethoprim
Trimipramine and other compounds structurally derived therefrom by substitution in the side chain
Trimustine
Trioxysalen
Tripelennamine except when included in Schedule 2 or 3
Triprolidine except when included in Schedule 2 or 3
Troxidone and other substances structurally derived from oxazolidinone with anticonvulsant properties when used for therapeutic purposes
Tylosin except:
- (a) when included in Schedule 6;
- (b) in animal feedstuffs for growth promotion in concentrations of 50 mg/kg or less of the total active antibiotic principle; or
- (c) in milk replacers for calves or starter rations for pigs in concentrations of 100 mg/kg or less of the total active antibiotic principle

Urethane (excluding its derivatives), for therapeutic use
Urethanes and ureides having or purporting to have soporific, hypnotic or narcotic properties not specifically included in this or any other schedule
Vaccines, sera, toxoids, and antigens for human parenteral use
Vaccines, veterinary live virus
Valnoctamide
Verapamil
Veratrum for therapeutic use
Vidarabine
Vinca alkaloids, including semi-synthetic derivatives
Vinyl ether when specifically prepared and packed as a therapeutic agent for the induction of inhalation anaesthesia

Viprynium
Virginiamycin except:
(a) when included in Schedule 6; or
(b) in animal feedstuffs for growth promotion in concentrations of 50 mg/kg or less of the total active antibiotic principle
Visnadine
Vitamin A in preparations containing more than 10 000 I.U. per recommended daily dosage for human use
Vitamin D in preparations containing more than 25 micrograms per recommended daily dosage for human use
Xanthine oxidase inhibitors including allopurinol
Xanthinol nicotinate
Xylazine
Yohimbine

SCHEDULE 5

Substances or preparations of a hazardous nature which must be readily available to the public but which require caution in handling, use and storage

Acetic acid (excluding its salts and derivatives) in preparations containing more than 30% acetic acid except when:
- (a) included in Schedule 2 or 6; or
- (b) for therapeutic use

Acetic anhydride (excluding its salts and derivatives) in preparations containing more than 30% acetic anhydride except when included in Schedule 6 for therapeutic use

Acetone when packed in containers of 20 litres or less, except:
- (a) in preparations containing 25% or less of acetone; or
- (b) when packed in containers of 60 ml or less

Aklomide

Alachlor

Alkaline salts, being the carbonate, orthosilicate, metasilicate or tribasic phosphate salts of sodium or potassium, and in any combination, except:
- (a) in preparations containing 10% or less of combined substances;
- (b) in solid preparations whose pH in 1% (w/v) aqueous solution is 11.5 or less; or
- (c) in liquid preparations having a pH of 11.5 or less

Alloxydim

Amitrole

Ammonia (excluding its salts and derivatives other than ammonium hydroxide) in preparations containing 5% or less of free ammonia except:
- (a) in medicinal preparations for internal use;
- (b) in appliances for inhalation in which the substance is absorbed upon an inert solid material; or
- (c) in preparations containing 0.5% or less of free ammonia

Ammonium thiocyanate

Arsenic, organic compounds of, in preparations containing 3% or less or arsenic, when prepared for use as herbicides or defoliants

Barium silicofluoride when coated on paper in an amount not exceeding 8 mg per cm^2

Bendiocarb in preparations containing 2% or less of bendiocarb

Bentazone

Benzoyl peroxide except when included in Schedule 3 or 4, or when used as an approved food additive

BHC (excluding the gamma-isomer) in preparations containing 10% or less of BHC

Bioallethrin including sinbioallethrin containing 10% or less of bioallethrin

Bioresmethrin, except in preparations containing 10% or less of bioresmethrin
Boric acid and Borax except:
(a) in preparations containing 1% or less of boron;
(b) in handcleaning preparations; or
(c) when included in Schedule 4
Buthidazole
2-tert-butylamino-4-ethylamino-6-methoxy-1,3,5-triazine
Cadmium sulphide in preparations containing 2.5% or less of cadmium sulphide for human therapeutic use
Camphor except:
(a) in preparations containing 10% or less of camphor; or
(b) when included in Schedule 2
Captafol
Carbaryl in preparations containing 10% or less carbaryl except when included in Schedule 2 or 4; or when impregnated in plastic resin strip material containing 20% or less of carbaryl
Chlordecone in preparations containing 5% or less of chlordecone
Chlorfenac
Chlorfenson
Chlorinating compounds and bleaches containing more than 4% of available chlorine, except:
(a) when included in Schedule 7; or
(b) when included elsewhere in this schedule
Chlornidine
Chlorocresol, except in preparations containing 3% or less chloroscresol
2-Chloro-N-[(4-Metaoxy-6-methyl-1,3,5-triazin-2-YL)amino-carbonyl] benzene sulphaonamide
1-(4-chlorophenoxy)-1-imidazol-1-YL-3,3-dimethyl-2-butanone in concentrations of more than 2% except when included in Schedules 4 or 6
Chloropropylate
Chlorothalonil
Copper sulphate except for internal human therapeutic use
4-CPA
Cuprimyxin for the treatment of animals
Cyanatryn
Cyanoacrylic acid esters
Cyanuric acid (excluding its salts and derivatives)
Cyclohexanone peroxide
Cypermethrin in preparations containing 10% or less of cypermethrin
2,4-D
2,4-DB
DDT in preparations containing 10% or less of DDT, except for human therapeutic use
2,4-DES
N,N-Diallyldichloroacetamide except in preparations containing 10% or less of N,N-diallyldichloroacetamide
Dicamba
Dichlone
Dichloroisocyanurates and in preparations containing more than 4% available chlorine

1-[2-,4-Dichlorophenyl-4-propyl-1,3-dioxalan-2-YL-methyl]-IH-1,2, 4-triazole, in concentrations of 20% or less
1-[2(2, 4-Dichlorphenyl)-2-(2-propenyloxy)ethyl]-1H-imidazole
3,6-Dichloropicolinic acid
Dichlorvos:
- (a) when impregnated in plastic resin strip material containing 20% or less dichlorvos;
- (b) sustained release resin pellets for veterinary use containing 20% or less dichlorvos; or
- (c) when in aerosol packs containing 10 grams or less of dichlorvos

Dicloran
Dicofol
Dimethirimol
Dimethylformamide in preparations containing 10% or less of dimethylformamide
Dinitramine
Diphenamid
Dodine
Epoxy resins, liquid, and all amines and organic anhydrides used as curing agents for epoxy resins
EPTC
Ethephon (excluding its salts and derivatives)
Ether preparations for use in internal combustion engines
Ethofumesate
2-[1-(Ethoxymino)butyl]-5-(2-ethylthiopropyl-3-hydroxy-2-cyclohexen-1-one(sethoxydim)
Ethoxyquin except in preparations containing 10% or less of ethoxyquin
Ethylene glycol when packed and labelled as a boiling point and/or freezing point modifier and containing 10 mg/kg of denatonium benzoate as a bittering agent
2^{1}-Ethyl-N-(2-methoxy-1-methylethyl)-6-methylchloro-acetanilide
Eucalyptus oil except in preparations containing 25% or less of eucalyptus oil
Fenarimol
Fenbutatin-oxide
Fenoprop
Fenson
Fenthion in preparations containing 20% or less of fenthion when packed in single-use containers having a capacity of 0.1 ml or less
Flamprop-methyl
Fluchloralin
Formic acid (excluding its salts and derivatives)
Fospirate when inpregnated in plastic resin strip material containing 20% or less of fospirate
Furalaxyl
Glyphosate
Hexazinone

Hydrocarbons, liquid, excluding kerosene, mineral turpentine, white petroleum spirit, toluene, xylene and light mineral and paraffin oils (but excluding their derivatives) distilling under 300°C, except:
- (a) toluene and xylene when included in Schedule 6;
- (b) in containers having a capacity of more than 20 litres;
- (c) in solids or semi-solid cleaning and polishing preparations;
- (d) in preparations containing 25% or less of a total of such liquid hydrocarbons;
- (e) in preparations packed in pressurised aerosol containers; or
- (f) in adhesives packed in containers each containing 50 grams or less of adhesive

Hydrochloric acid (excluding its salts and derivatives) in preparations containing 10% or less of hydrochloric acid (HCl) except:
- (a) in preparations containing 0.5% or less of hydrochloric acid (HCl); and
- (b) for therapeutic use

Hydrofluoric acid and hydrosilicofluoric acid in preparations containing 0.5% or less of hydrofluoric acid or hydrosilicofluoric acid except in substances containing 15 mg/kg or less of fluoride ion

Hydrogen peroxide (excluding its salts and derivatives) except in preparations containing 6% (20 vol) or less of hydrogen peroxide

Iodofenphos

2-Iso-butylamino-4-ethylamino-6-methoxy-1,3,5-triazine

Isopropyl-N-(3-ethyl-N-phenylcarbamoyloxy) phenylcarbamate

Kerosene when packed in containers of 20 litres or less except in preparations containing 25% or less of kerosene

Lead compounds, in preparations for use as hair cosmetics

Levamisole in preparations containing 15% or less of levamisole for the treatment of animals

Lindane in preparations containing 10% or less of lindane except when included in Schedule 2

Maldison in preparations containing 10% or less of maldison except:
- (a) when included in Schedule 2; or
- (b) in other preparations containing 2% or less maldison;

Mancozeb

Maneb

MCPA

MCPB

Mecoprop

Mepiquat

Metaldehyde in preparations containing 2% or less of metaldehyde

Methabenzthiazuron

Methazole

Methiocarb in pelleted preparations containing 2% or less of methiocarb

Methoxychlor

Methylated spirits: methylated spirit, industrial, as defined by the *Commonwealth Spirits Act* 1906, except in containers having a capacity of more than 5 litres
Methylene chloride except when used in aerosols
Methyl ethyl ketone when packed in containers of 20 litres or less except in preparations containing 25% or less of ketones included in Schedule 5
Methyl ethyl ketone peroxide
Methyl iso-amyl ketone when packed in containers of 20 litres or less, except in preparations containing 25% or less of ketones included in Schedule 5
Metho-iso-butyl ketone when packed in containers of 20 litres or less except in preparations containing 25% or less of ketones included in Schedule 5
Methyl N-(Methoxyacetyl)-N-(2,6-XYLYL)alaninate
3-(Methylsulfonyl)butanon-o-methyl carbamoyloxim in solid preparations containing 10% or less
Metiram
Metolachlor
Metribuzin
Mezineb
Mineral turpentine when packed in containers of 20 litres or less except in preparations containing 25% or less of mineral turpentine
NAA
Naled when impregnated in plastic resin strip material containing 20% or less of naled
Naphthalene as such
Naphthalene acetic acid, except in preparations containing 25% or less of naphthalene acetic acid
Nitric acid (excluding its salts and derivatives) in preparations containing 10% or less of nitric acid as such, except preparations containing 0.5% or less of nitric acid
Norbormide
Organo-tin compounds not elsewhere included in this schedule in preparations containing 1% or less of such compounds
Oxycarboxin
Oxythioquinox
Para-dichlorobenzene
Pebulate
Pendimethalin
Peracetic acid in concentrations of 10% or less
Petrol when packed in containers of 20 litres or less except preparations containing 25% or less of petrol
ortho-Phenylphenol except in preparations containing 3% or less ortho-phenylphenol
Phosphonic acid, except in preparations containing 10% or less phosphonic acid
Phosphoric acid, excluding its salts and derivatives except:

(a) when packed in containers with a capacity of not less than 10 litres and labelled with the word "CORROSIVE", in bold face sans serif capital letters of a height of not less than 1 cm;

(b) in preparations containing 350 g/litre or less of phosphoric acid;
(c) in solid and semi-solid preparations; or
(d) in professional dental kits

Pirimicarb in preparations containing 0.5% or less pirimicarb

Poly (hexamethylene biguanide) hydrochloride

Potassium hydroxide (excluding its salts and derivatives) in preparations containing 5% or less of potassium hydroxide, except:
(a) in preparations containing 0.5% or less of potassium hydroxide; or
(b) in accumulators and batteries

Potassium sulphide in preparations for metal treatment in containers each containing 50 grams or less of potassium sulphide

Prometryn

Propanil

Propionic acid (excluding its salts and derivatives) in preparations containing more than 30% propionic acid, except:
(a) when included in Schedule 6; or
(b) for therapeutic use

Propoxur:
(a) in dust preparations containing 3% or less of propoxur; or
(b) in granular sugar based fly baits containing 1% or less of propoxur providing that the preparationalso contains a dark colouring agent and separate bittering agent

Prynachlor

Pyrethrins and related compounds except in preparations containing 10% or less of such compounds

Pyrethrins, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids except in preparations containing 10% or less of such substances

N-3-Pyridylmethyl-N'-p-nitrophenylurea in preparations containing 10% or less of N-3-pyridylmethyl-N'-p-nitrophenylurea

Pyrithione zinc in preparations containing 2% or less of pyrithione zinc

Quaternary ammonium compounds and in preparations containing more than 10% quaternary ammonium compounds except when included in any other schedule

Quintozene

Salicylanilide

S-benzyl N,N-Dl-(sec-butyl)-thiolocarbamate

Selenium sulphide in preparations containing 2.5% or less of selenium sulphide for topical therapeutic use

Sodium chlorate

Sodium hydrogen sulphate

Sodium hydroxide (excluding its salts and derivatives) in preparations containing 5% or less of sodium hydroxide except in preparations containing 0.5% or less of sodium hydroxide

Sodium nitrite except:
(a) in preparations containing 1% or less of sodium nitrite; or
(b) for therapeutic use

Sodium sulphide in preparations for metal treatment in containers each containing 50 grams or less of sodium sulphide

Styrene (excluding its derivatives) when packed in containers of 20 litres or less

Sulphamic acid, except in preparations containing 10% or less of sulphamic acid

2,3,6-TBA

TDE in preparations containing 10% or less TDE

Terbuthylazine

Terbutryn

Tetrachloroethylene in preparations containing 5% or less tetrachloroethylene except:
(a) when prepared for use for the treatment of humans and for the treatment of animals; or
(b) when packed in containers of 50 ml or less

Tetrachlorvinephos

Thiobencarb

Triadimenol

Tri-allate

Trichloroacetic acid, alkali salts of

1,1,1-trichloroethane when packed in containers of 20 litres or less except:
(a) in preparations containing 25% or less of 1,1,1-trichloroethane;
(b) when used in aerosols other than for therapeutic use; or
(c) when packed in containers of 50 ml or less

Trichloroisocyanuric acid when compressed in block form for use in swimming pools

Trietazine

Turpentine oil when packed in containers of 20 litres or less except in preparations containing 25% or less of turpentine oil

Vernolate

Warfarin, in rodent baits containing 0.1% or less of warfarin

Zineb

Ziram

SCHEDULE 6

Substances or preparations of a poisonous nature which must be readily available to the public for domestic, agricultural, pastoral, horticultural, veterinary, photographic or industrial purposes or for the destruction of pests

Acephate
Acetic acid (excluding its salts and derivatives) in preparations containing more than 80% acetic acid, except when included in Schedule 2
Acetic anhydride (excluding its salts and derivatives) in preparations containing more than 80% of acetic anhydride, except:
- (a) when included in Schedule 5; or
- (b) for therapeutic use

Acifluorfen
Aldrin
Allidochlor
Alpha-chlorohydrin
Ametryn
Amidithion
2-Amino-butane
Aminocarb in preparations containing 25% or less of aminocarb
2-Amino-5-diethylamino toluene
2-Amino-5-N-ethyl-N-B (hydroxy ethyl) amino toluene
2-Amino-5-N-ethyl-N-B (methane sulphonamide ethyl) amino toluene
2-Amino-5-N-ethyl-N-B (methoxyethyl amino toluene) di-p-toluene
Amitraz
Ammonia (excluding its salts and derivatives other than ammonium hydroxide) except:
- (a) in preparations containing 5% or less of free ammonia;
- (b) in medicinal preparations for internal use; or
- (c) in applicances for inhalation in which the substance is absorbed in an inert solid material

Aniline (excluding its salts and derivatives) except in preparations containing 1% or less of aniline
Arecoline
Arsenic:
- (a) in ant poisons containing 0.5% or less arsenic trioxide;
- (b) organic compounds of arsenic prepared for use as herbicides or defoliants except when included in Schedule 5;
- (c) in animal feedstuff premixes containing 4% or less of arsenic; or
- (d) in preparations for therapeutic use in animals except when included in Schedule 4

Azemethiphos
Azobenzene
Azocyclotin

Bacitracin in animal feedstuff premixes for growth promotion purposes containing concentrations greater than 50 mg/kg but not more than 20,000 mg/kg of the total antibiotic principle
Barban
Barium, salts of (except barium sulphate, except:
(a) paint containing barium metaborate; or
(b) when included in Schedule 5
Bendiocarb:
(a) in wettable powders containing 80% or less of bendiocarb and when packed in containers or primary packs containing not less than 100 grams of bendiocarb;
(b) in wettable powders containing 20% or less of bendiocarb and not less than 0.002% of denatonium benzoate and when packed in containers or primary packs containing not less than 48 grams of bendiocarb and when used as a fly control preparation;
(c) soluble granular preparations containing 5% or less of bendiocarb; or
(d) except when included in Schedule 5
Benquinox
Bensulide
5-Benzylfur-3-ylmethyl (1'R,3'S.E) - 2', 2'-dimethyl-3'-(2-oxo-2,3,4,5-tetrahydro-3-thienylidenemethyl)-cyclopropane carboxylate
Benzylpenicillin including procaine penicillin in preparations for intramammary infusion in animals, containing not more than 100,000 international units per dose of benzylpenicillin or procaine penicillin, when suitably coloured with Brilliant Blue FCF or other approved colour as a marker and when packed in applicator devices specially designed for the purpose
Beryllium
BHC (excluding the gamma-isomer) except when included in Schedule 5
Binapacryl
Bithionol for treatment of animals
Bromoform except for therapeutic use
Bromadioline in preparations containing 0.1%
3-(3-(4'-Bromodiphenyl-4-YL)-1,2,3,4-tetrahydronaphthyl-4-hydroxycoumarin) in preparations containing 0.25% or less
Bromophos
Bromophos-ethyl
Bromoxynil
Brotianide
Bunamidine
Butacarb
2-butoxy-2'-thiocyano-diethyl ether
Butynorate
Cadmium, compounds of, except when included in Schedule 5
Cambendazole
Camphechlor
Carbadox except in animal feestuffs containing 50 mg/kg or less of the total active principle
Carbaryl except when included in Schedule 2, 4 or 5

Carbon disulphide
alpha-Chloralose, when prepared for use as a pesticide
Chlordane
Chlordecone except in preparations containing 5% or less of chlordecone
Chlorfenethol
Chlormequat
N-[5-chloro-4-[(4-chlorophenyl]-cyanomethyl]-2-methyl-phenyl]-2-hydroxy-3,5-diiodobenzamide
Chloromethiuron
Chlorophacinone
1-(4-chlorophenoxy)-1-imidazol-1-yl-3,3-dimethyl-2-butanone in concentrations of more than 40% except when included in Schedule 4
Chloropicrin in preparations containing 5% or less of chloropicrin
Chlorpyrifos
Chlorpyrifos-methyl
Chlortetracycline in preparations:

(a) for topical application to animals for ocular use only; or
(b) for intramammary infusion in animals, containing not more than 100,000 international units per dose of chlortetracycline when suitably coloured with Brilliant Blue FCF or other approved colour as a marker and when packed in applicator devices specially designed for the purpose

Chlorthiamid
Chromates and dichromates
Chromium trioxide (excluding its salts and derivatives)
Coumaphos in preparations containing 5% or less of coumaphos
Coumarin derivatives and phenylindanedione derivatives not elsewhere included in the Schedules
Coumatetralyl
Crotoxyphos
Crufomate
Cyanazine
Cyclosulfyne
Cyhexatin
Cypermethrin except when included in Schedule 5
Cythioate
Dazomet
DDT and in preparations containing more than 10% of DDT, except for human therapeutic use
Demeton-O-methyl and demeton-S-methyl in preparations containing 50% or less of one or both demeton-O-methyl and demeton-S-methyl
Di-allate
Diazinon
Dichlofenthion
Dichloroenthyl ether
1-[2-(2-,4-Dichlorophenyl)-4-ethyl-1,3-dioxolan-2-yl-methyl]-1H-1, 2, 4-triazole
O-[2,4-Dichlorophenyl]-O-ethyl-s-propylphosphorodithioate

1-[2-(2-,4-dichlorophenyl)-4-propyl-1,3-dioxalan-2-yl-methyl]-IH-1, 2, 4-triazole, except when included in Schedule 5
N-(3,4-Dichlorophenyl)-N'-[2-(2" sulfoxy-4'-Chlorphenoxy) -5 Chlorphenyl] urea (sodium salt)
1,2-Dichloropropane
1,3-Dichloropropene
Dichlorvos in preparations containing 50% or less dichlorvos except when included in Schedule 5
Dichlofop-methyl
Dieldrin
Diethylene dioxide
N,N-Diethyl-p-phenylene diamine
Difenzoquat
2,3-Dihydro-5, 6-dimethyl-1, 4-dithin-1, 1,4,4-tetraoxide
Dihydrostreptomycin in preparations for intramammary infusion in animals containing not more than 100,000 international units per dose of dihydrostreptomycin when suitably coloured with Brilliant Blue FCF or other approved colour as a marker and when packed in applicator devices specially designed for the purpose
Dimethanonaphthalene and all substitution and/or addition products not elsewhere included in these schedules
Dimethoate
1,3-Di (methoxycarbonyl)-1-propen-2-yl-dimethyl phosphate in preparations containing 25% or less of 1,3-di (methoxycarbonyl)-1-propen-2-yl-dimethyl phosphate
Dimethyl formamide except when included in Schedule 5
2-(2',4'-Dimethyl-phenylimino)-3-methyl-4-thiazoline
Dimethyl sulphoxide except for therapeutic use
Dimetilan in preparations containing 25% or less of dimetilan
Dimetridazole
Dinitrocresols, dinitrophenols and their homologues in preparations containing 5% or less of such compounds, except for therapeutic use
Dinocap
Dioxacarb
Diphacinone
Diquat
Disulfiram except for therapeutic use
Disulfoton in granular preparations containing 5% or less of disulfoton
Dithianon
Dithiazanine in preparations containing 2% or less of dithiazanine for the treatment of animals
Dithiocarbamates when prepared for agricultural, pastoral or horticultural purposes, except when included in Schedule 5
3,3'-Di-(trifluoromethyl)-4,4'-dichloro-n,n'-diphenylurea
Diuredosan
Econazole for external animal use
Endosulfan
Endothal
Epichlorohydrin except in preparations containing 2% or less of epichlorohydrin

Erythromycin in preparations:
- (a) for intramammary infusion in animals, containing not more than 100 000 international units per dose of erythromycin, when suitably coloured with Brilliant Blue FCF or other approved colour as a marker and when packed in applicator devices specially designed for the purpose; or
- (b) in animal feedstuff premixes for growth promotion purposes containing concentrations greater than 50 mg/kg but not more than 20,000 mg/kg of the total antibiotic principle

Ether solvent
Ethiofencarb
Ethoate-methyl
Ethoprophos in granular formulations containing 10% or less of ethoprophos
Ethyl bromide
Ethylene chlorohydrin
Ethylene dibromide
Ethylene dichloride
Ethylene glycol, when packed and labelled as an anti-freeze, except when included in Schedule 5
Ethylene oxide
Etridiazole
Famphur in preparations containing 20% or less of famphur
Fenaminosulf in preparations containing 10% or less of fenaminosulf when labelled and packed as dry seed dressings
Fenamiphos in granular preparations containing 5% or less of fenamiphos
Fenazaflor
Fenchlorphos
Fenitrothion
Fenthion except when included in Schedule 5
Fenvalerate
Ferbam
Ferrocyanides and ferricyanides except in preparations containing 1% or less of such substances
Flavophospholipol in animal feedstuff premixes for growth promotion purposes containing concentrations greater than 50 mg/kg but not more than 20,000 mg/kg of the total antibiotic principle
Formaldehyde (excluding its derivatives) except in preparations containing 5% or less of formaldehyde
Formothion
Fospirate except when included in Schedule 5
Fumagillin
Guazatine
HCB
Heptachlor
Hexachlorophane in preparations for the treatment of animals
Hydrazine
Hydrochloric acid (excluding its salts and derivatives) except in preparations containing 10% or less of hydrochloric acid (HCl)

Hydrofluoric acid and hydrosilicofluoric acid and other fluorine compounds except:
- (a) when used for human therapeutic purposes;
- (b) in dentifrices containing 1000 mg/kg or less of fluoride ion;
- (c) in preparations containing 3% or less of sodium fluoride or sodium silicofluoride when used as preservatives;
- (d) when included in Schedule 2, 4, 5 or 7;
- (e) in substances containing 15 mg/kg or less of fluoride ion; or
- (f) ammonium fluosilicate in preparations containing 3.2% or less of ammonium fluosilicate for pesticide purposes

Hydroquinone except:
- (a) when included in Schedule 4; or
- (b) in preparations containing 10% or less hydroquinone

Hygromycin in animal feedstuff premixes for use as an anthelmintic containing concentrations greater than 50 mg/kg but not more than 20,000 mg/kg of hygromycin

Imidocarb

Iodine (excluding its salts and derivatives):
- (a) in iodophors, except those containing 1.5% or less available iodine;
- (b) in other liquid preparations containing 2.5% or less of available iodine; or
- (c) in preparations for animal treatment only, except in iodophors containing 1.5% or less of available iodine or in solid or semi-solid preparations containing 2.5% or less of available iodine

Ioxynil

Iron compounds, in preparations for the treatment of animals

Isocyanates, free organic, except in paints containing 0.1% or less of free organic isocyanates

Kitasamycin: in animal feedstuff premixes for growth promotion purposes containing concentrations greater than 100 mg/kg but not more than 20,000 mg/kg of the total antibiotic principle

Lasalocid except in animal feedstuffs containing 100 mg/kg or less of the total active antibiotic principle

Laurylisoquinolinium bromide

Lead compounds except:
- (a) in preparations for therapeutic use;
- (b) in preparations for cosmetic use, except when included in Schedule 5; or
- (c) in pencil cores, finger colours, showcard colours, pastels, crayons, poster paints/colours or coloured chalks containing 0.01% of less of lead

Lindane except when included in Schedule 5 or Schedule 2

Maldison except when included in Schedule 5 or Schedule 2

Mebendazole for the treatment of animals

Meclofenamic acid for the treatment of animals

Menazon

Mercuric iodide when prepared for use for agricultural, industrial, pastoral or horticultural purposes
Mercuric thiocyanate when prepared for use for photographic purposes
Mercurous chloride except preparations for internal use
Mercury, organic compounds of, when prepared for use for agricultural, pastoral or horticultural purposes except when included in Schedule 7
Metacresolsuplohonic acid and formaldehyde condensation products for animal use
Metaldehyde except when included in Schedule 5
Metham-sodium
Methiocarb except when included in Schedule 5
Methomyl in fly-baits containing 1% or less of methomyl and not less than 0.002% of denatonium benzoate as a bittering agent
0-2-Methoxycarbonylprop-1-enyl-o,0-dimethylphosphorothioate
Methyl alcohol (excluding its salts and derivatives) except in methylated spirit
Methylene bisthiocyanate except in preparations containing 1% or less of methylene bisthiocyanate
Methyl chloride
Methyl isothiocyanate
1-(B methyl sulphonamide ethyl)-2-amino-3-n,n-diethylamino benzene
3-Methylsulfonyl)butanon-o-methylcarbamoyloxim except when included in Schedule 5
Molinate
Monensin in animal feedstuff premixes containing greater than 33 mg/kg but not more than 125,000 mg/kg of the total active principle
Naled except when included in Schedule 5
Naphthalophos when specifically prepared and packed for use as a sheep drench
Neomycin in preparations for topical application to animals for ocular use only
Nicotine in preparations containing 3% or less of nicotine when labelled and packed for the treatment of animals
Nimidane in preparations containing 25% or less of nimidane
Nithiamide, except in preparations containing 20% or less of nithiamide
Nitric acid (excluding its salts and derivatives) except in preparations containing 10% or less of nitric acid as such
Nitrobenzene except:
    (a) in solid or semi-solid polishes;
    (b) in soaps containing 1% or less of nitrobenzene; or
    (c) in preparations containing 0.1% or less of nitrobenzene
Nitrophenols, ortho, meta and para
Nitroscanate
Nitroxynil
Novobiocin in preparations for intramammary infusion in animals, containing not more than 100,000 international

units per dose of novobiocin, when suitably coloured with Brilliant Blue FCF or other approved colour as a marker and when packed in applicator devices specially designed for the purpose

2-n-Octyl-4-isothiazolin-3-one

Oetradiol-17-beta in silicone rubber implants for use as growth promotant in bovine cattle

Olaquindox when intended for use as a growth promotant in pigs, except in animal feedstuffs containing 100 mg/kg or less of the total active principle

Oleandomycin in animal feedstuff premixes for growth promotion purposes containing concentrations greater than 50 mg/kg but not more than 20,000 mg/kg of the total antibiotic principle

Omethoate in preparations containing 50% or less of omethoate

Organo-tin compounds, being di-alkyl, tri-alkyl and tri-phenyl tin compounds where the alkyl group is methyl, ethyl, propyl or butyl not elsewhere included in these schedules except:

(a) in plastics;

(b) in paints containing 3% or less of such compounds calculated as a proportion of the non-volatile content of the paint; or

(c) in other preparations containing 1% or less of such compounds

Orthodichlorobenzene

Oxadiazon

Oxalic acid (excluding its salts and derivatives) and soluble oxalates

Oxantel embonate for the treatment of animals

Oxfendazole

Oxyclozanide

Oxytetracycline in preparations:

(a) for topical application to animals for ocular use only; or

(b) for intramammary infusion in animals, containing not more than 100,000 international units per dose of oxytetracycline, when suitably coloured with Brilliant Blue FCF or other approved colour as a marker and when packed in applicator devices specially designed for the purpose

Paraquat in granular preparations containing 3% or less of paraquat

Parbendazole

Pentachlorophenol except in preparations containing 0.5% or less of pentachlorophenol

Peracetic acid except when included in Schedule 5

Perfluidone

Permanganates

Phenethicillin in preparations for intramammary infusion in animals, containing not more than 100,000 international units per dose of phenethicillin, when suitably coloured with Brilliant Blue FCF or other approved colour as a marker and when packed in applicator devices specially designed for the purpose

Phenkapton in preparations containing 50% or less of phenkapton
Phenol and any homologue of phenol boiling below 220°C, creosote, except:
(a) preparations containing 3% or less by weight of such substances or homologues; and
(b) for therapeutic use
Phenoxymethyl penicillin in preparations for intramammary infusion in animals, containing not more than 100,000 international units per dose of phenoxymethyl penicillin, when suitably coloured with Brilliant Blue FCF or other approved colour as a marker and when packed in applicator devices specially designed for the purpose
Phenylene diamines and alkylated phenylene diamines, not elsewhere specified in this schedule:
(a) when used in hair dyes;
(b) in preparations packed and labelled for photographic purposes; or
(c) in preparations packed and labelled for testing water except diethyl- or dimethyl-para-phenylene diamine in tablets containing 10 mg or less in opaque strip packaging labelled for water testing
Phosalone
Phosmet
Phosphides, metallic
Phosphorus yellow (excluding its salts and derivatives) in preparations containing 0.5% or less of free phosphorus
Phoxim
Picric acid (excluding its derivatives) except in preparations containing 5% or less of picric acid
Pindone
Piperophos
Pirimicarb
Pirimiphos-ethyl
Pirimiphos-methyl
Potassium bromate except in preparations containing 0.5% or less of potassium bromate
Potassium cyanate
Potassium hydroxide except in preparations containing 5% or less of potassium hydroxide
Profenofos
Progesterone in a silicone rubber elastomer when used as a controlled-release implant for synchronisation of oestrus in cattle
Promacyl
Promecarb in preparations containing 50% or less of promecarb
Propachlor
Propetamphos
Propionic acid (excluding its salts and derivatives):
(a) in preparations containing more than 80% propionic acid; or
(b) except for therapeutic use
Propoxur except when included in Schedule 2 or 5
Pyrazophos

N-3-Pyridylmethyln'-p-nitrophenylurea except when included in Schedule 5

Rafoxanide

Salinomycin in animal feedstuff premixes containing greater than 60 mg/kg but not more than 60,000 mg/kg of the total active antibiotic principle

Selenium, compounds of,

- (a) in preparations containing 2.5% or less of selenium;
  - (i) when packed and labelled for the blueing of gun barrels; or
  - (ii) when packed and labelled for photographic purposes;
- (b) in preparations containing 0.1% or less of selenium when packed and labelled as vaccines, drenches or pastes for treatment of animals;
- (c) in preparations containing 0.5% or less of selenium when packed and labelled as other injections for treatment of animals; or
- (d) in premixes containing 2% or less of selenium when packed and labelled for incorporation into animal feeds to provide 0.1 g/tonne or less of selenium

Sodium bromate except in preparations containing 0.5% or less of sodium bromate

Sodium hydroxide (excluding its salts and derivatives) except:

- (a) in preparations containing 0.5% or less of sodium hydroxide; or
- (b) when included in Schedule 5

Spiramycin in animal feedstuff premixes for growth promotion purposes containing concentrations greater than 50 mg/kg but not more than 20,000 mg/kg of the total antibiotic principle

Streptomycin in preparations for intramammary infusion in animals, containing not more than 100,000 international units per dose of streptomycin, when suitably coloured with Brilliant Blue FCF or other approved colour as a marker and when packed in applicator devices specially designed for the purpose

Strychnine in grain baits containing 0.5% or less of strychnine and registered as a pesticide

Sulfallate

Sulphanilamide and its derivatives unless elsewhere specified in this Schedule when packed and labelled for treatment of ornamental caged birds or ornamental fish only

Sulphaquinoxaline when packed and labelled for use as a coccidiostat in poultry except preparations containing 200 mg/kg or less of sulphaquinoxaline

Sulphuric acid (excluding its salts and derivatives) except:

- (a) in accumulators, batteries and fire extinguishers; or
- (b) in preparations containing 0.5% or less of sulphuric acid (H_2SO_4)

Sulprophos
2,4,5-T
TCA (excluding its salts and derivatives)
TCMTB (2-[thiocyanomethylthio]benzothiazole)
TDE except when included in Schedule 5
Temephos
Terpenes, chlorinated
Testosterone propionate, testosterone dipropionate and testosterone enanthate in preparations labelled for the treatment of pizzle (sheath) rot in wethers, and in preparations labelled for masculination of wethers for use as "teaser rams" to stimulate and detect reproductive activity in ewes
Tetrachloroethylene except:
- (a) when prepared for use for the treatment of humans and for the treatment of animals;
- (b) when packed in containers of 50 ml or less; or
- (c) when included in Schedule 5

Tetracycline in preparations:
- (a) for topical applications to animals for ocular use only;
- (b) for intramammary infusion in animals, containing not more than 100,000 international units per dose of tetracycline, when suitably coloured with Brilliant Blue FCF or other approved colour as a marker and when packed in applicator devices specially designed for the purpose; or
- (c) when packed and labelled for treatment of ornamental caged birds or ornamental fish only

Tetradifon
Tetramisole, including Levamisole, in preparations for the treatment of animals except when included in Schedule 5
Thiazafluron
Thiometon
Thiourea except for therapeutic use
Thiram
ortho-Tolidine when packed and labelled in concentrations of 0.1% or less of ortho-tolidine for the testing of water
Toluene (excluding its derivatives), when packed in containers of 20 litres or less, except:
- (a) in preparations containing 50% or less or toluene or of both toluene and xylene; or
- (b) when packed in containers of 50 ml or less

Triadimefon
S,s,s-Tributylphosphorothioate
Trichloroethylene except:
- (a) when specifically prepared for medicinal purposes; or
- (b) when packed in containers of 50 ml or less

Trichlorophenol
Trichlorfon
Triclopyr
Tridemorph
Triethyl phosphate

Tylosin and its salts in animal feedstuff premixes for growth promotion purposes containing concentrations greater than 50 mg/kg but not more than 20,000 mg/kg of the total antibiotic principle

Vamidothion

Virginiamycin in animal feedstuff premixes for growth promotion purposes containing concentrations greater than 50 mg/kg but not more than 20,000 mg/kg of the total antibiotic principle

Warfarin except:

(a) for therapeutic use; or

(b) when included in Schedule 5

Xylene (excluding its derivatives), when packed in containers of 20 litres or less except:

(a) in preparations containing 50% or less of xylene or of both xylene and toluene; or

(b) when packed in containers of 50 ml or less

Zeranol, in implants for use as a growth promotant in steer cattle

Zinc chloride except in preparations containing 5% or less of zinc chloride

Zinc p-phenolsulphonate except in preparations containing 5% or less of zinc p-phenolsulphonate

Zinc sulphate except for human therapeutic use and in preparations containing 5% or less of zinc sulphate

---

SCHEDULE 7

Substances or preparations of exceptional danger which require special precautions in manufacture and use and for which special individual labelling and distribution regulations may be required

Acrolein
This substance should be available only to specially licensed operators and for approved research and industrial processes

Aldicarb
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Allyl alcohol
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Aminocarb except when included in Schedule 6
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

4-Aminopyridine
This substance should be available only to specially licensed operators and for research purposes

Amiton
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Antu
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Aprinocid
This substance should be available for toxicological research purposes only

Arsenic, except:
- (a) for the specific purposes shown in Schedules 4, 5 or 6;
- (b) in inorganic form on open sale for pesticide use in quantities sufficiently large to discourage domestic use;
- (c) to authorized persons;
- (d) for manufacture or research; or
- (e) in animal feedstuffs containing 75 mg/kg or less of arsenic

Azinphos-ethyl
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Azinphos-methyl
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Bendiocarb except when included in Schedule 5 or 6
This substance should be available to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Benzene (excluding its derivatives) except:
(a) preparations containing 1.5% v/v or less of benzene; or
(b) petrol containing 5% v/v or less of benzene
This substance should be available only for approved users, research and industry

Bethahydroxyethylhydrazine
This substance should be available only to bona fide pineapple growers, industry and for research purposes

Bromadiolone except when included in Schedule 6.
This compound may be supplied only in concentrates for the preparation of rodent baits, or as rodent baits as specified in Schedule 6

3-(3-(4'-Bromodiphenyl-4-yl)-1,2,3,4-tetrahydronaphthyl)-4-hydroxycoumarin) except when included in Schedule 6.
This compound may be supplied only in concentrates for the preparation of rodent baits, or as rodent baits as specified in Schedule 6

Campheclor
This substance should be available only to licensed pest control operators, bona fide primary producers, for approved pesticide purposes and for research purposes

Carbofuran
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Carbon tetrachloride
This substance should be available only for approved users, research and industry

Carbophenothion
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Chlordimeform
For authorized research purposes and/or for use on cotton when applied from aircraft in specified areas

Chlorfenvinphos
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Chlorine (excluding its salts and derivatives)
This substance should be available only for approved users, research and industry

Chloropicrin except when included in Schedule 6
This substance should be available only for approved users, research and industry

5-Chloro-3-methyl-4-nitropyrazole
This substance should be available only to bona fide citrus growers and for research purposes

Chlorthiophos except when included in Schedule 6
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Clomiphene and other products specifically prepared to stimulate ovulation
These substances should be available only on prescription or order of qualified specialists practising in the fields of gynaecology and/or obstetrics or for the purpose of the conduct of medical or scientific research including veterinary trials under the direction of veterinary surgeons

Coumaphos except when included in Schedule 6
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

S-alpha-Cyano-m-phenoxybenzyl (IR,3R)-3-(2,2-dibromovinyl) -2, 2-dimethylcyclopropane
Carboxylate for domestic use, it should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Cyanides - see hydrocyanic acid

Cyclofenil
These substances should be available only on prescription or order of qualified specialists practising in the fields of gynaecology and/or obstetrics or for the purpose of the conduct of medical or scientific research including veterinary trials under the direction of veterinary surgeons

(R,S)-alpha-Cyano-3-phenoxybenzyl=(IRS)-cis-3-(Z-2-chloro-3,3,3-trifluoroprop-1-enyl)-2,2-dimethylcyclopropane-carboxylate
This substance should be available only to licensed pest control operators and bona fide primary producers, for use as a cattle dip or spray, and for research purposes

Demeton
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Demeton-o-methyl and demeton-s-methyl except when included in Schedule 6
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Dialifos
This substance should be available only to licensed fumigators, for approved research purposes and for approved industrial purposes

1,2-dibromo-3-chloropropane for approved toxicological research purposes only

Dichlorvos except when included in Schedule 5 or 6
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Dicrotophos
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Dimefox
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

1,3-Di(methoxycarbonyl)-1-propen-2-yl-dimethyl phosphate except when included in Schedule 6
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Dimetilan except when included in Schedule 6
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Dinitrocresols, dinitrophenols and their homologues and in preparations containing more than 5% of such compounds, except for therapeutic use. These substances should be available only for approved users, research and industry

Dioxathion
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Disulfoton except when included in Schedule 6
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Endrin
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Ethion
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Ethoprophos except when included in Schedule 6
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Ethoxyethyl mercury chloride
This substance should be available for approved research purposes and industry only. It should not be available for use as pesticide

Ethyl mercury chloride
This substance should be available for approved research purposes and industry only. It should not be available for use as pesticide

Famphur except when included in Schedule 6
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Fenaminosulf except when included in Schedule 6
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Fenamiphos except when included in Schedule 6
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Fensulphothion
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Fenthionethyl
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Fluoracetamide
This substance should be available only to accredited Governmental Vermin Control Officers and for approved research purposes

Fluoroacetic acid
This substance should be available only to accredited Governmental Vermin Control Officers and for approved research purposes

Formetanate
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Halofuginone except in prepared stockfeeds containing 3 g/tonne or less of halofuginone

Hydrocyanic acid except:

(a) in preparations containing the equivalent of 0.15% or less of hydrocyanic acid; or

(b) for therapeutic use

This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes, for approved industrial use and for research purposes

Isocarbophos
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Isofenphos
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Ivermectin for approved research purposes only

Leptophos
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Mazidox
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Mecarbam
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Mercuric chloride when prepared for use for agricultural, industrial, pastoral or horticultural purposes
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Methamidophos
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Methapyrilene, for research purposes or for purposes approved by Commonwealth and or State authorities

Methidathion
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Methfuroxam for approved toxicological research purposes only

Methomyl except when included in Schedule 6
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Methyl bromide
This substance should be available only to licensed fumigators, for approved research purposes and for approved industrial purposes

Mevinphos
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Mipafox
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Mirex
This substance should be available only for use by persons and projects approved by government authority

Monocrotophos
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Naphthalophos except when included in Schedule 6
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Nicotine except:
(a) when included in Schedule 4 or 6; or
(b) in tobacco
This substance should be available for approved research purposes and industry only. It should not be available for use as a pesticide

Nimidane except when included in Schedule 6
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Nitrofen for approved toxicological research purposes only

Omethoate except when included in Schedule 6
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Oxamyl
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Paraquat except when included in Schedule 6
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Parathion
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Parathion-methyl
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Phenkapton except when included in Schedule 6
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Phorate
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Phosfolan
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Phosphamidon
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Polychlorinated biphenyls
These substances should be available for approved research purposes and for use in totally enclosed systems. They should not be used in industries which handle, process or store foods, animal feedstuffs or packaging materials

Promecarb except when included in Schedule 6
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Prostaglandins
These substances should be available only to medical practitioners and veterinary surgeons with a specialised knowledge and experience with these types of substances, and for approved research purposes

Schradan
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Silver sulphadiazine
This substance should be made available only to hospitals for the treatment of major burns and for the treatment of patients where full-thickness skin loss has occurred

Strychnine except when included in Schedule 1, 4 or 6
This substance should be available only to licensed pest control operators, bona fide primary producers on authority for approved pesticide purposes and for research purposes except when included in Schedule 6

Sulfotep
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Sulphatroxazole, except when included in Schedule 4

Tepp
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Terbufos
This substance should be available only in granular form containing a maximum 15% W/W of terbufos, to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Tetrachloroethane
This substance should be available only for approved industrial use and approved research purposes

Thalidomide
This drug should be available only to leprologists for treatment of erythema nodosum leprosum

Thallium
This substance should be available only to accredited Governmental Vermin Control Officers and for approved research purposes

Thiofanox
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

ortho-Tolidine except when included in Schedule 6 and in solid -state diagnostic therapeutic reagents. Approved scientific research and approved industrial processes

Triamiphos

Triazbutil
This substance should be available only to licensed pest control operators, bona fide primary producers for approved pesticide purposes and for research purposes

Trichloroisocyanuric acid except:

(a) in preparations containing 4% or less of available chlorine; or

(b) when included in Schedule 5

This substance should be available only for approved users, research and industry

Vinyl chloride

This substance should be available to industry but only for use in closed chemical operations and for approved research purposes

---

SCHEDULE 8

Substances or preparations which are addiction producing or potentially addiction producing, including those so classified by the United Nations Organization or its agencies

Acetyldihydrocodeine except when included in Schedule 2 or 4
Acetylmethadol (3-acetoxy-6-dimethylamino-4,4-diphenyl-heptane)
Allylprodine (3-allyl-1-methyl-4-phenyl-4-propionoxy-piperidine)
Alphacetylmethadol (alpha-3-acetoxy-6-dimethylamino-4, 4-diphenylheptane)
Alphameprodine (alpha-3-ethyl-1-methyl-4-phenyl-4-propionoxypiperidine)
Alphamethadol (alpha-6-dimethylamino-4, 4-diphenyl-3-heptanol)
Alphaprodine (alpha-1,3-dimethyl-4-phenyl-4-propionoxy-piperidine)
Amphetamine
Anileridine (1-para-aminophenethyl-4-phenylpiperidine-4-carboxylic acid ethyl ester)
Benzethidine (1-(2-benxyloxyethyl)-4-phenylpiperdine-4-carboxylic acid ethyl ester)
Benzylmorphine (3-benzylmorphine)
Betacetylmethadol (beta-3-acetoxy6dimethylamino-4,4-diphenylheptane)
Betameprodine (beta-3-ethyl-1-methyl-4-phenyl-4-propionoxypiperidine)
Betamethadol (beta-6-dimethylamino-4,4-diphenyl-3-heptanol)
Betaprodine (beta-1,3-dimethyl-4-phenyl-4-propionoxy-piperdine)
Bezitramide (1-(2-cyano-3,3-diphenylpropyl)-4-(2-oxo-3-propionyl-1-benzimidazolinyl)piperidine)
Clonitazene (2-para-chlorbenzyl-1-diethylaminoethyl-5-nitrobenzimidazole)
Cocaine (methyl ester of benzoylecgonine), and any solution or dilution in an inert substance whether liquid or solid in any proportion and all preparations and admixtures
Coca leaf
Codeine (3-methylmorphine) except when included in Schedule 2, 3 or 4
Codeine-n-oxide
Codoxime (dihydrocodeinone-6-carboxymethyloxime)
Concentrate of poppy straw (the material arising when poppy straw has entered into a process for concentration of its alkaloids)
Dexamphetamine
Dextromoramide ((+)-4-(2-methyl-4-oxo-3,3-diphenyl-4-(1-pyrrolindyl butyl) morpholine)
Dextropropoxyphene, (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-butanol propionate)

Diampromide (n(-2-(methylphenethlamino) propyl) propionanilide)
Diethylthiambutene (3-diethylamino-1,1-di(2'-thieny-1-) -1-butene)
Difenoxin (1-(3-cyano-3,3-diphenylpropyl)-4-phenylisonipecotic acid) except when included in Schedule 4
Dihydrocodeine except when included in Schedule 2 or 4
Dihydromorphine
Dimenoxadol (2-dimethylaminoethyl-1-ethoxy-1, 1-diphenylacetate
Dimepheptanol (6-dimethylamino-4,4-diphenyl-3-heptanol)
Dimethylthiambutene (3-dimethylaminol,1-di(2'-thienyl)-1-butene)
Dioxaphetyl butyrate (ethyl 4-morpholino-2,2-diphenylbutyrate)
Diphenoxylate (1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine 4-carboxylic acid ethyl ester) except when included in Schedule 4
Dipipanone (4,4-diphenyl-6-piperidine-3-heptanone)
Drotebanol (3,4-dimethoxy-17-methylmorphinan-6 B, 14-diol)
Ecgonine, its esters and derivatives which are convertible to ecgonine and cocaine
Ethylmethylthiambutene (3-ethylmethylaminol,1-di(2'-thienyl) -1-butene)
Ethylmorphine (3-ethylmorphine) except when included in Schedule 2 or 4
Etonitazene (1-diethylaminoethyl-2-para-ethoxybenzy-15-nitrobenzimidazole)
Etoxeridine (1-(2-(2-hydroxyethoxy) ethyl-4-phenylpiperidine-4-carboxylic acid ethyl ester)
Fentanyl (1-phenethyl 4-N-propionyl-anilino piperidine)
Furethidine (1-(2-tetrahydrofurfuryloxyethyl)-4-phenylpiperidine-4-carboxylic acid ethyl ester)
Heptane derivatives - having addiction properties, not specifically included in this Schedule
Hydrocodone (dihydrocodeinone)
Hydromorphinol (14-hydroxydihdromorphine)
Hydromorphone (dihydromorphinone)
Hydroxypethidine (4-meta-hydroxyphenyl-1-methylpiperidine -4-carboxylic acid ethyl ester)
Isomethadone (6-dimethylamino-5-methyl-4,4-diphenyl-3-hexanone
Levomethorphan ((-)-3-methoxy-N-methylmorphinan)
Levomoramide ((-)-4-(2-methyl-4-oxo-3,3-diphenyl-4-(1-pyrrolidinyl) butyl morpholine)
Levophenacylmorphan ((-)-3-hydroxy-N-phenacylmorphinan)
Levorphanol ((-)-3-hydroxy-n-methylmorphinan)
Mecloqualone 3-(o-chlorophenyl)-2-methyl-4-(3H) quinazolinone
Metazocine (2'-hydroxy-2,5,9-trimethyl-6,7-benzomorphan)
Methadone (6-dimethylamino-4,4-diphenyl-3-heptanone)
Methadone intermediate (4-cyano-2-dimethylamino-4, 4-diphenylbutane)
Methaqualone
Methlamphetamine
Methyldesorphine (6-methyl-delta-6-desoxymorphine)
Methyldihydromorphine (6-methyldihydromorphine)

Methylphenidate
1-Methyl-4-phenylpiperidine-4-carboxylic acid esters
Metopon (5-methyldihydromorphinone)
Moramide intermediate (2-methyl-3-morpholino-1,1-diphenyl-propane carboxylic acid)
Morpheridine (1-(2-morpholinoethyl)-4-phenylpiperidine 4-carboxylic acid ethyl ester)
Morphine
Morphine derivatives not specifically included in this Schedule
Morphine methobromide and other pentavalent nitrogen morphine derivatives
Morphine-N-oxide
Morphine substitutes not specifically included in this Schedule
Myrophine (myristylbenzylmorphine)
Nicocodine (6-nicotinylcodeine) except when included in Schedule 2 or 4
Nicodicodine (6-nicotinoyldihydrocodeine) except when included in Schedule 2 or 4
Nicomorphine (3,6-dinicotinylmorphine)
Noracymethadol ((±)-alpha-3-acetoxy-6-methylamino-4, 4-diphenylheptane
Norcodeine (N-demethylcodeine) except when included in Schedule 2 or 4
Norlevorphanol ((-)3-hydroxymorphinan)
Normethadone (6-dimethylamino-4,4-diphenyl-3-hexanone)
Normorphine (N-demethylated morphine)
Norpipanone (4,4-diphenyl-6-piperidine-3-hexanone)
Opium in any form except the alkaloids noscapine and papaverine
Oxycodone (14-hydroxydihydrocodeinone)
Oxymorphone (14-hydroxydihydromorphinone) except when included in Schedule 4
Pentazocine
Pethidine (1-methyl-4-phenylpiperidine-4-carboxylic acid ethyl ester)
Pethidine intermediate A (4-cyano-1-methyl-4-phenyl-piperidine)
Pethidine intermediate B (4-phenylpiperidine-4-carboxylic acid ethyl ester)
Pethidine intermediate C (1-methyl-4-phenylpiperidine-4-carboxylic acid)
Phenadoxone (6-morpholino-4, 4-diphenyl-3-heptanone)
Phenampromide (N(1-methyl-2-piperidinoethyl) propion-anilide)
Phenazocine (2-hydroxy-5,9-dimethyl-2'-phenethyl-6, 7-benzomorphan)
Phencyclidine
Phenmetrazine
Phenomorphan (3-hydroxy-N-phenethylmorphinan)
Phenoperidine (1-(3-hydroxy-3-phenylpropyl)-4-phenyl-piperidine-4-carboxylic acid ethyl ester)
Pholcodine (morpholinylethyl morphine) except when included in Schedule 2 or 4
Piminodine (4-phenyl-1-(-3-phenylaminopropyl) piperidine-4-carboxylic acid ethyl ester)

Piperidine derivatives having addiction properties, not specifically included in this Schedule
Piritramide (-1-(3-cyano-3,3-diphenylpropyl)-4-(1-piperidino) piperidine-4-carboxylic acid amide)
Proheptazine (1-,3-dimethyl-4-phenyl-4-propionoxyazacylcloheptane)
Properidine (1-methyl-4-phenylpiperidine-4-carboxylic acid isopropyl ester)
Propiram
Racemethorphan ((±)-methoxy-N-methylmorphinan)
Racemoramide ((±)-4-(2-methyl-4-oxo-3,3-diphenyl-4-(1-pyrrolidinyl) butyl morpholine)
Racemorphan ((±)-3-hydroxy-N-methylmorphinan)
Sufentanil N-(4-(methoxymethyl)-1-(2-(2-thienyl)-ethyl-4-piperidyl) propionanilide
Thebacon (acetyl dihdrocodeinone)
Thebaine
Tilidene (±)ethyl-trans-2-(dimethylamine)-1-phenyl-3-cyclohexene-1-carboxylate
Trimeperidine(1,2,5-trimethyl-4-phenyl-4-propionoxy-piperidine)